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BAYESIAN-DERIVED VANCOMYCIN AUC 24H THRESHOLD FOR NEPHROTOXICITY
IN SPECIAL POPULATIONS
Abstract
By Dan Ho
University of the Pacific
2021
A Bayesian-derived 24-hour area under the concentration-time curve over minimum
inhibitory concentration from broth microdilution (AUC 24h/MICBMD) ratio of 400 to 600 is
recommended as the new monitoring parameter for vancomycin to optimize efficacy and
minimize nephrotoxicity. The AUC24h threshold of 600 mg*h/L for nephrotoxicity was
extrapolated from studies that assessed the general population. It is unclear if this upper
threshold is consistent or varies when used in special populations such as critically ill patients,
obese patients, patients with preexisting renal disease, and patients on concomitant nephrotoxins.
The purpose of this study is to investigate the generalizability of the proposed
vancomycin AUC24h threshold of 600 mg*h/L for nephrotoxicity. The objective is to determine
the optimal Bayesian-derived AUC24h threshold to minimize vancomycin-associated
nephrotoxicity in special populations such as critically ill patients, obese patients, patients with
preexisting renal disease, and patients on concomitant loop diuretics, ACEIs, ARBs, NSAIDs,
aminoglycosides, piperacillin-tazobactam, and IV contrast dyes.
The study design is a single-center, retrospective cohort study. For each patient,
nephrotoxicity was assessed and the Bayesian-derived AUC 24h was estimated. Using
classification and regression tree (CART) analysis, the AUC 24h threshold for nephrotoxicity was
determined for each special population that had at least ten nephrotoxic patients. The predictive
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performances (e.g., positive predictive value [PPV], negative predictive value [NPV], sensitivity,
specificity, and area under the receiver operating characteristic [ROC] curve) of each CARTderived threshold were then compared to the guideline threshold’s predictive performances.
PPV and sensitivity were given greater weight when comparing the thresholds.
Of the 336 patients, 29 (8.6%) nephrotoxic patients were observed after initiating
vancomycin. Among the special populations of interest, critically ill patients, obese patients,
patients with preexisting renal disease, and patients on concomitant loop diuretics included at
least ten nephrotoxic patients and thus were further analyzed to determine the CART-derived
AUC24h thresholds. The CART-derived AUC 24h thresholds were 544 mg*h/L for critically ill
patients (n=116), 586 mg*h/L for obese patients (n=111), 539 mg*h/L for patients with
preexisting renal disease (n=54), and 543 mg*h/L for patients on concomitant loop diuretics
(n=126). Compared to the guideline threshold of 600 mg*h/L, the CART-derived thresholds for
critically ill patients, patients with preexisting renal disease, and patients on concomitant loop
diuretics had comparable PPVs but significantly higher sensitivities. On the other hand, the
CART-derived threshold for obese patients did not have a significantly different PPV, NPV,
sensitivity, specificity, and area under the ROC curve.
For critically ill patients, patients with preexisting renal disease, and patients on
concomitant loop diuretics, a lower vancomycin AUC24h threshold for nephrotoxicity such as
544 mg*h/L, 539 mg*h/L, and 543 mg*h/L, respectively, may be considered to minimize the
risk of nephrotoxicity. On the other hand, this study supports the continued use of the guideline
threshold of 600 mg*h/L to minimize the risk of nephrotoxicity in obese patients.
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CHAPTER 1: INTRODUCTION

Background
Vancomycin is a bactericidal glycopeptide antibiotic that remains a mainstay of treatment
for methicillin-resistant Staphylococcus aureus (MRSA) and other severe gram-positive
infections.1,2 When given intravenously, vancomycin demonstrates characteristics of a doseresponse and dose-toxicity relationship with a narrow therapeutic index which warrants careful
dosing and monitoring of the antibiotic.
Previously published vancomycin therapeutic monitoring consensus guidelines
recommended trough concentrations as a surrogate marker for the 24-hour area under the
concentration-time curve over minimum inhibitory concentration (AUC 24h/MIC) ratio due to a
history of difficulty in obtaining multiple vancomycin concentrations and subsequently
calculating the area under the concentration-time curve over 24 hours (AUC 24h).1 However, an
enhanced method of using Bayesian software programs has been shown to generate accurate and
reliable estimates of the AUC24h. Additionally, studies have shown a high degree of
interindividual variability between a trough concentration and its respective AUC 24h.9 A
simulation of 5,000 vancomycin concentration versus time profiles derived from administering
1,000 milligrams every eight hours examined the relationship between trough concentrations and
AUC24h values.3 In the study, trough concentrations correlated with less than 50% of the AUC 24h
values (R2=0.409). Trough concentrations are suspected to be poor surrogate markers for
AUC24h values as a trough concentration is a single exposure point after a dose is administered
while the AUC24h represents the cumulative drug exposure over 24 hours. Furthermore, no link
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between treatment success and vancomycin trough concentrations was demonstrated throughout
the entire trough continuum.3
On the other hand, with high vancomycin concentration targets, specifically 15 to 20
mg/L, there is a considerable concern for unnecessarily high AUC 24h values that can put patients
at an increased risk of vancomycin-associated nephrotoxicity. 4 Compared to trough-based
monitoring, studies have shown that AUC24h-based monitoring significantly decreased the
incidence of vancomycin-associated nephrotoxicity.5,6 In a retrospective, quasi-experimental
study, Finch et al. assessed 546 patients dosed using trough concentrations versus 734 patients
dosed using AUC24h.6 They determined that AUC24h-based monitoring was associated with a
significantly lower incidence of vancomycin-associated nephrotoxicity (OR, 0.52; 95% CI, 0.340.80; p=0.003). Cox proportional hazards regression also revealed similar results (hazard ratio
[HR], 0.53; 95% CI, 0.35-0.78; p=0.002). Moreover, Neely et al. conducted a prospective
observational study consisting of 252 patients and compared trough-based monitoring in the first
year versus AUC24h-based monitoring in the second and third year.7 Nephrotoxicity occurred in
8% of the patients in the first year and occurred in 0% and 2% of the patients in the second and
third year, respectively. Compared to AUC24h-based monitoring, trough-based monitoring had
significantly higher rates of trough concentrations greater than 15 mg/L (p<0.001) and
vancomycin-associated nephrotoxicity (p=0.01).
Over the past decade, trough-based monitoring for vancomycin has been well integrated
into practice despite limited evidence on the clinical benefits of maintaining trough
concentrations between 15 to 20 mg/L for serious MRSA infections. However, in March 2020,
the American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of
America (IDSA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious
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Diseases Pharmacists (SIDP) published an updated vancomycin therapeutic monitoring
consensus guideline that recommends AUC24h-based monitoring over trough-based monitoring
for patients with suspected or definitive serious MRSA infections. 4 Due to the guideline’s
updated recommendation, more clinicians and hospital institutions are in the midst of
transitioning or expected to transition to AUC24h-based monitoring for vancomycin.
Introduction to Research
The 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring guideline no longer
recommends trough-based monitoring with a target of 15 to 20 mg/L for patients with serious
MRSA infections.4 Additionally, it recommends a Bayesian-derived AUC 24h/MIC from broth
microdilution (AUC24h/MICBMD) ratio of 400 to 600, as the new optimal pharmacokinetics (PK)
and pharmacodynamics (PD) target for vancomycin. Rybak et al. concluded that AUC 24h-based
monitoring using an AUC24h/MICBMD ratio of 400 to 600 optimizes clinical efficacy and
minimizes nephrotoxicity risk in patients with serious MRSA infections such as bacteremia,
pneumonia, and osteomyelitis.
The vancomycin AUC24h threshold of 600 mg*h/L for nephrotoxicity was primarily
extrapolated from studies that assessed the general population. 4,8-12 They demonstrated that
AUC24h values greater than thresholds ranging from 550 to 800 mg*h/L were significantly
associated with an increased likelihood of nephrotoxicity. 1-6 It is unclear if this upper threshold
is consistent or varies when used in special populations such as critically ill patients, obese
patients, patients with preexisting renal disease, and patients on concomitant nephrotoxins. 4 ICU
patients and obese patients were shown to be associated with a significantly higher risk of
vancomycin-associated nephrotoxicity.9,13-16 Preexisting renal disease and concomitant
nephrotoxins were also shown to play a synergistic role with vancomycin in increasing the risk
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of vancomycin-associated nephrotoxicity. 17-20 However, literature assessing the vancomycin
AUC24h threshold for nephrotoxicity in the aforementioned special populations is limited and
warrants further investigation.
Definition of Terms
Definitions of the terms commonly used in this study are defined in Table 1.
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Table 1
Key Terms and Definitions
Term

Definition
The area under the concentration-time curve over 24 hours
AUC24h
which represents the cumulative drug exposure over 24 hours.
The lowest concentration of an antibiotic that completely
MIC
inhibits the growth of a microorganism in vitro.
The 24-hour area under the concentration-time curve over MIC
AUC24h/MIC
ratio.
The highest serum concentration reached by a drug following
Peak Concentration
an administered dose.
The lowest serum concentration reached by a drug before the
Trough Concentration
next dose is administered.
The state when the rate of drug intake equals its rate of
Steady State
elimination.
The prediction of PK parameters and dosing regimens by
Bayesian PK
integrating information gathered from population PK and the
patient’s measured drug levels.
The use of classification to create a predictive model that
CART Analysis
predicts the value of an outcome or dependent variable using
known values of explanatory variables.
Used in this study to refer to the vancomycin AUC 24h threshold
CART-Derived Threshold
for nephrotoxicity that was derived from this study’s CART
analysis.
Used in this study to refer to the vancomycin AUC 24h threshold
of 600 mg*h/L for nephrotoxicity recommended by the 2020
Guideline Threshold
ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring
guideline.
The probability of patients with a positive screening test truly
PPV
having the condition.
The probability of patients with a negative screening test truly
NPV
not having the condition.
The proportion of patients with a condition who are correctly
Sensitivity
identified by a screening test as truly having that condition.
The proportion of patients without a condition who are
Specificity
correctly identified by a screening test as truly not having that
condition.
A combined measure of sensitivity and specificity which
Area under the ROC Curve numerically provides the overall predictive performance of a
screening test or diagnostic test.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; MIC, minimum
inhibitory concentration; AUC24h/MIC, 24-hour area under the concentration-time curve over the
minimum inhibitory concentration ratio; PK, pharmacokinetics; CART, classification and
regression tree; PPV, positive predictive value; NPV, negative predictive value; ROC, receiver
operating characteristic.
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Purpose and Objectives
The purpose of this study is to investigate the generalizability of the proposed
vancomycin AUC24h threshold of 600 mg*h/L for nephrotoxicity. The primary objective is to
determine the optimal Bayesian-derived AUC24h threshold to minimize vancomycin-associated
nephrotoxicity in special populations such as intensive care unit (ICU) or critically ill patients
and obese patients. In addition, this study investigated the optimal Bayesian-derived AUC 24h
threshold for nephrotoxicity in patients with preexisting renal disease and patients on
concomitant nephrotoxins other than vancomycin.
Research Questions
1. For each special population, what is the CART-derived AUC 24h threshold for vancomycinassociated nephrotoxicity?
a. ICU or Critically Ill Patients
b. Obese Patients
c. Patients with Preexisting Renal Disease
d. Patients on Concomitant Nephrotoxins
i. Loop diuretics
ii. Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor
Blockers (ARBs)
iii. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
iv. Aminoglycosides
v. Piperacillin-Tazobactam
vi. Intravenous (IV) Contrast Dyes
2. For each special population, how do the predictive performances (i.e., positive predictive
value [PPV], negative predictive value [NPV], sensitivity, specificity, and area under the
ROC curve) of the CART-derived AUC24h threshold and guideline threshold compare to one
another?
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a. ICU or Critically Ill Patients
b. Obese Patients
c. Patients with Preexisting Renal Disease
d. Patients on Concomitant Nephrotoxins
i. Loop diuretics
ii. ACEIs or ARBs
iii. NSAIDs
iv. Aminoglycosides
v. Piperacillin-Tazobactam
vi. IV Contrast Dyes
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CHAPTER 2: REVIEW OF THE LITERATURE

Methods to Estimate Vancomycin AUC24h
In a retrospective observational study, vancomycin’s efficacy and safety were shown to
be more closely related to AUC24h and AUC24h/MIC ratio versus trough concentrations.21 Given
vancomycin’s narrow range to optimize efficacy and minimize nephrotoxicity, an accurate
method of calculating the AUC24h is needed.4 Until recently, the traditional method of using
multiple PK samples and the linear-trapezoidal formula was used to calculate AUC 24h. However,
the practical difficulties of this method for vancomycin monitoring are why trough
concentrations were originally used as surrogate markers for AUC 24h.4 Pai et al. proposed two
simplified approaches that were shown to have a high precision and low bias despite only using
one to two vancomycin concentrations. 3
The first approach relies on Bayesian software programs, population modeling, and one
or more vancomycin concentrations to estimate the AUC 24h.3 By using a Bayesian approach,
probabilities defined as the Bayesian priori and Bayesian posteriori are predicted. 22 The
Bayesian priori uses a population PK model and identifies demographic, pathophysiological,
environmental, and drug-related factors that can impact vancomycin’s disposition.
Vancomycin’s PK parameters and AUC24h are estimated for each patient by predicting how
vancomycin will behave based on prior knowledge about the parameters of interest from
previous patient population data. Contrastingly, the Bayesian posteriori involves using patientspecific information such as trough concentrations and peak concentrations to revise or update
the estimations of the PK parameters of interest and AUC 24h.22 The Bayesian method is shown
to be as accurate as the traditional first-order PK method of using the linear-log trapezoidal
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rule.23 Using a dataset derived from 19 ICU patients, Turner et al. compared the AUC values
estimated by multiple Bayesian dose-optimizing software programs to the AUC values
calculated using the linear-log trapezoidal rule (AUC REF). The study obtained vancomycin
serum levels during the vancomycin infusion, at the end of the infusion, at 60, 120 and 300
minutes after the infusion, and immediately before the next dose of vancomycin. In the study,
accuracy was defined as the median ratio of the estimated AUC to AUC REF and bias was defined
as the median of the absolute value of the percentage difference between the estimated AUC
from AUCREF [(|AUC – AUCREF|/AUCREF) x 100]. With one to two vancomycin concentrations,
the Bayesian method produced average accuracy ratios of 0.80 or higher and a bias of less than
20% which are expected to be adequate when targeting an AUC 24h of 400 to 600 mg*h/L.23
The second approach proposed by Pai et al. uses first-order PK equations and two steady
state vancomycin concentrations that are obtained during the same dosing interval. 3 With this
method, a trough concentration and peak concentration are obtained to create a simple monoexponential curve. The snapshot of the patient’s vancomycin dosing regimen is then used, along
with first-order PK equations, to calculate the AUC 24h. With a dataset of 47 intensively sampled
adults who received vancomycin, Pai et al. used a Bayesian-derived AUC 24h from all
vancomycin samples inputted as a reference to assess the accuracy of the second approach which
only used two vancomycin samples. Their results showed that the simplified equation-based
approach tends to underpredict or overpredict the AUC24h by 2% or less which they deemed as
clinically insignificant.9
Despite having a similar accuracy as the Bayesian method, the second approach has a
major downfall of only being able to provide a static estimation of the AUC 24h during the
specific time period when the concentration levels were collected. 23 Therefore, the second
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approach must be used at steady state and does not account for continuing acute physiologic
changes such as renal impairment that can occur during or after the collecting period. Slight lab
errors during the collecting period of the two samples can also make a considerable impact on
the estimation of the PK values. For example, a vancomycin concentration that is collected too
early may still be in the alpha phase and lead to erroneous estimates of the rate of elimination for
the simple mono-exponential curve. Contrastingly, the Bayesian method can use vancomycin
concentrations obtained at any time. It can estimate the AUC 24h at steady state despite the
sample being drawn before steady state. This is especially advantageous for patients who are
limited on being able to achieve steady state such as critically ill patients. Another downfall to
using first-order PK equations is that it creates a simple mono-exponential curve rather than
capturing vancomycin’s two-compartment distribution and elimination. 23 On the other hand, the
Bayesian method allows for application of multiple PK models including a two-compartment
model. It can also be modified to be an adaptive program that can account for different dosing
patterns such as when loading doses are given or when covariates such as creatinine clearance
are unstable.3
Therefore, this study followed the first approach proposed by Pai et al. to estimate the
AUC24h values.3 The Bayesian software program used in this study was PrecisePK (Version
20.02.00, Healthware Inc., San Diego, CA) and one or more trough concentrations were used to
calculate the Bayesian posteriori.
AUC24h/MIC Threshold for Vancomycin’s Efficacy
The broth microdilution (BMD) method and Etest are the two most common methods to
estimate the minimum inhibitory concentration (MIC) of staphylococci. The Etest generally
predicts the MIC to be 1.5- to 2-fold higher than the MIC calculated using the BMD method after
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log conversion.24 An AUC24h/MICBMD ratio of 400 to 600 approximately corresponds to an
AUC24h/MICEtest ratio of 200 to 400. For vancomycin dosing in nonserious infections, the
variability between the methods to estimate the MIC can be insignificant. However, the
standardization and confirmation of the MIC method is imperative for patients with serious
MRSA infections who require prompt achievement of the target AUC 24h/MIC ratio. Therefore,
the 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring guideline recommends using
the BMD method to estimate the MIC as most AUC 24h/MIC ratio data were generated using
MICBMD.4 Currently, an AUC24h/MICBMD ratio greater than or equal to 400 is recommended as
the optimal PK target for vancomycin’s efficacy for serious MRSA infections.
The AUC24h/MICBMD ratio of greater than or equal to 400 is supported by in vitro and in
vivo research on the PK and PD of vancomycin. 4,25 Animal model studies demonstrated a 1- to
2-log reduction in bacterial inoculum when the vancomycin AUC 24h/MICBMD ratio is greater than
400.4 Additionally, in vitro data on two strains of methicillin-susceptible Staphylococcus aureus
(MSSA) and MRSA showed that an AUC 24h/MICBMD ratio less than 400 increases vancomycin
resistance and the development of vancomycin-intermediate Staphylococcus aureus strains. The
vancomycin MIC of both strains increased from 1 mg/L to 4 mg/L within 144 hours of
subtherapeutic vancomycin exposure.25
Initially, studies on the relationship between AUC/MIC ratio and the clinical efficacy of
vancomycin were small-scale retrospective studies that used a formula-based approach to
estimate the AUC values.2,4,12,26-28 Moise et al. retrospectively evaluated patients with hospitalacquired pneumonia due to MSSA or MRSA.28 Based on 70 patients, Moise-Broder et al.
determined that there was a significantly higher clinical success rate in patients with
AUC24h/MICBMD ratios greater than or equal to 350 (odds ratio [OR], 7.19; 95% CI, 1.91-27.3;
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p=0.0036). Additionally, the median duration for bacteriological eradication of MSSA and
MRSA was significantly shorter for patients with AUC 24h/MICBMD ratios greater than or equal to
350 (10 days vs. excess of 30 days; p=0.0402).28 Similar methods were done on studies
evaluating patients with MRSA bacteremia.2,26,27 Kullar et al. conducted a retrospective cohort
study of 320 adults with MRSA bacteremia and identified an AUC 24h/MICBMD threshold of 421
using a classification and regression tree (CART) analysis.2 Patients with AUC24h/MICBMD
ratios less than 421 had a significantly higher rate of treatment failure (61.2% vs. 48.6%;
p=0.038). Likewise, Holmes et al. and Jung et al. assessed patients with MRSA bacteremia and
reported similar AUC24h/MICBMD thresholds.26,27 Holmes et al. followed a multicenter
observational cohort of 182 adults. Patients who achieved an AUC 24h/MICBMD ratio greater than
373 had a significantly lower rate of 30-day mortality (71.6% vs. 84.3%; p=0.043).27 Jung et al.
assessed 76 patients with MRSA bacteremia and determined that an AUC 24h/MICBMD ratio less
than 398.5 was associated with a higher rate of treatment failure (45.0% vs. 23.2%; p=0.065).26
In a retrospective cohort study of 44 patients with MRSA bacteremia, Mogle et al. used the
trapezoidal rule and two-point PK approach to estimate AUC 24h.12 Patients with
AUC24h/MICBMD ratios greater than or equal to 297 had a greater than 2.7-fold increase in
clinical success (94.4% vs. 50.0%; p=0.01).
Instead of using the formula-based approach, recent studies used the Bayesian method to
estimate the AUC values.21,29 In a retrospective study of 123 cases of MRSA bacteremia, Lodise
et al. determined that treatment failure significantly decreased when day 1 AUC 0-24h/MICBMD
ratios were greater than 521 (relative risk [RR], 0.54; 95% CI, 0.32-0.91; p=0.02). Patients with
AUC24-48h/MICBMD ratios greater than 650 on day 2 also had a significant reduction in treatment
failure (RR, 0.58; 95% CI, 0.34-0.99; p=0.05).21 Casapao et al. evaluated 139 patients with
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definite or possible MRSA infective endocarditis. Even after adjusting for factors such as
presence of heterogenous vancomycin-intermediate Staphylococcus aureus, ICU admission, IV
drug use, previous hospitalization, and age, they determined that treatment failure remained
significantly higher for patients with AUC 0-24h/MICBMD ratios less than or equal to 600 (aOR,
2.331; 95% CI, 1.012-5.371; p=0.047).29
Two studies used a similar Bayesian approach to estimate AUC 24h but only used MICEtest
to calculate the AUC24h/MIC ratio.30,31 Brown et al. included 18 patients with infected
endocarditis and 32 patients with complicated bacteremia (e.g., patients with two positive blood
cultures and metastatic foci of the infection).30 They determined that patients who had
AUC24h/MICEtest ratios less than 211 had a greater than 4-fold increase in death (38% vs. 8%;
p=0.02). On the other hand, Garwonoski et al. evaluated 59 patients who had MRSA bacteremia
and osteomyelitis.31 Patients with AUC24h/MICEtest ratios greater than 293 were associated with a
2.5-fold decrease in time to microbiological clearance (4 ± 2 days vs. 6 ± 3 days; p=0.01). Due
to the MICEtest usually being 1.5- to 2-fold higher than the MIC BMD, the AUC24h/MICEtest
thresholds are suspected to align with the AUC24h/MICBMD thresholds determined by previous
studies.21,29-31
The extrapolation of using an AUC/MIC BMD ratio of 400 to 600 is limited because it is
primarily based on retrospective, single-center analyses. Therefore, Lodise et al. conducted a
prospective, multicenter study that assessed the relationship between AUC/MIC ratios on day 2
and clinical outcomes in 265 adult patients with MRSA bacteremia. 32 No AUC/MICBMD
threshold for vancomycin’s clinical efficacy was identified due to only 20% of the study
population having AUC/MICBMD ratios less than 400 mg*h/L. They recommended to continue
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maintaining an AUC/MICBMD ratios greater than 400 mg*h/L as it remains unclear if
vancomycin’s clinical efficacy is maintained below that threshold.
The vancomycin AUC24h/MICBMD target is primarily derived from patients with
Staphylococcus aureus bacteremia, pneumonia, osteomyelitis, and endocarditis. 4 Hence,
research on the AUC24h/MICBMD threshold in other MRSA-associated infections such as skin and
soft tissue infections (SSTI), necrotizing fasciitis, infected hardware, and septic joints and in
vancomycin special populations such as amphetamine users, IV drug users (IVDU), critically ill
patients, and patients on concomitant immunosuppressants is warranted. The current study
initially included the objective of assessing the aforementioned MRSA-associated infections and
vancomycin special populations and their AUC 24h/MICBMD thresholds for clinical efficacy.
However, the study was unable to accomplish this objective due to limitations explained in
Chapter 5.
AUC24h Threshold for Vancomycin-Associated Nephrotoxicity
An AUC24h of 600 mg*h/L is currently recommended as the upper threshold for
vancomycin to minimize the risk of nephrotoxicity.4 The threshold was based on collective
literature that showed the risk of vancomycin-associated nephrotoxicity increases along the AUC
continuum and is at its highest when AUC24h is greater than 550 to 800 mg*h/L.
In a retrospective study of 31 patients, Suzuki et al. compared the highest Bayesianderived AUC24h values during the treatment period versus the occurrence of nephrotoxicity. 8 A
majority of the patients who did not develop nephrotoxicity had AUC 24h values between 400 to
600 mg*h/L while most patients who experienced nephrotoxicity had AUC 24h values between
600 to 800 mg*h/L (p=0.014). Allen et al. conducted a retrospective cohort study of 278
patients.32 They compared the incidence of nephrotoxicity between patients with AUC 0-24h
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values less than 700 mg*h/L and patients with AUC 0-24h values greater than 700 mg*h/L.33
Patients above the prespecified threshold had a significantly higher incidence of nephrotoxicity
(24.5% vs. 13.1%; p=0.021).
Moreover, studies identified CART-derived vancomycin AUC thresholds for
nephrotoxicity and suggested that the risk of nephrotoxicity increases in relation to AUC 24h.33-36
Lodise et al. assessed 166 patients and calculated AUC 0-24h using a Bayesian method.33 They
observed that an AUC0-24h greater than or equal to 1,300 mg*h/L increased the risk of
vancomycin-associated nephrotoxicity (25.9% vs. 10.1%; p=0.05). Zasowski reported similar
findings in a multicenter, retrospective study of 323 patients. 34 The incidence of nephrotoxicity
significantly increased when AUC0-24h was greater than or equal to 677 mg*h/L, AUC24-48h was
greater than or equal to 683 mg*h/L, and AUC0-48h was greater than or equal to 1218 mg*h/L. In
a retrospective study of 127 patients, Chavada et al. also demonstrated a similar relationship
between AUC0-24h and vancomycin-associated nephrotoxicity. 35 Patients with AUC0-24h values
greater than the CART-derived threshold of 565 mg*h/L had a significantly greater risk of
nephrotoxicity (40% vs. 11.2%; p=0.002). Furthermore, Chavada et al. observed that the risk of
nephrotoxicity increased by 0.2% as AUC 0-24h increased by 1 mg*hr/L (OR, 1.002; 95% CI,
1.001-1.004; p=0.021). Lastly, Lodise et al. conducted a multicenter, prospective observational
study of 265 adults with MRSA bacteremia and determined that the risk of AKI continually
increased as AUC24-48h increased. In their study, patients with AUC 24-48h values greater than or
equal to 793 mg*h/L had the highest risk of AKI (RR, 0.16; 95% CI, 0.04-0.29). 36
Aljefri et al. conducted a meta-analysis on randomized case-control and cohort studies
that reported AUC values and the incidence of nephrotoxicity. 10 Including the aforementioned
studies, the meta-analysis consisted of six retrospective studies and two prospective studies. The
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studies estimated AUC using a Bayesian approach with the exception of the study by Finch et al.
Because the studies reported multiple AUC values (e.g., AUC 0-24h and AUC24-48h) that ranged
from 550 to 700 mg*h/L, an endpoint of 650 mg*h/L was used to define low versus high AUC
values. Patients with low AUC0-24h values had a significantly lower risk of AKI than those with
high AUC0-24h values (OR, 0.36; 95% CI, 0.23-0.56; p<0.001). Patients with low AUC24-48h
values also had similar results (OR, 0.68; 95% CI, 0.46-0.99; p=0.002).4 Similarly, Mogle et al.
identified a CART-derived AUC24h threshold of 710 mg*h/L.12 Patients with AUC24h values
greater than or equal to 710 mg*h/L within the first 96 hours of vancomycin had a higher rate of
nephrotoxicity (33.3% vs. 2.5%; p=0.04).
The aforementioned studies defined vancomycin-associated nephrotoxicity as an increase
in serum creatinine (SCr) by greater than or equal to 0.5 mg/dL or a 50% increase from baseline
on two or more consecutive measures.8,12,32-36 However, this study defined vancomycinassociated nephrotoxicity as an increase in SCr by 0.3 mg/dL or more within 48 hours while on
vancomycin or an increase in SCr by 1.5 times the baseline which is known or presumed to have
occurred within seven days of discontinuing vancomycin. 37 A less stringent definition of
vancomycin-associated nephrotoxicity was used to include more nephrotoxic patients.
Additionally, studies did not examine the vancomycin AUC 24h thresholds for nephrotoxicity in
vancomycin special populations.8,12,32-36 Rather, they assessed the thresholds for the general
population of patients who were on vancomycin. More studies are needed to determine if the
vancomycin AUC24h threshold for nephrotoxicity is altered in certain vancomycin special
populations. This is especially important for vancomycin special populations that are associated
with an increased risk of vancomycin-associated nephrotoxicity such as the ones discussed in the
next section.
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Vancomycin PK and PD Changes in Special Populations
Studies on the use of vancomycin in special populations such as critically ill patients,
obese patients, patients with preexisting renal disease, and patients on concomitant nephrotoxins
showed that the PK and PD of vancomycin can be altered as a result of physiological
changes.13,17,18,20,24,38-40 Thus, these special populations can have an increased risk of adverse
effects from vancomycin. Host-related factors such as critical illness, increased weight,
preexisting renal disease, and concomitant nephrotoxic agents have been associated with an
increased risk of vancomycin-associated nephrotoxicity. 14-16,33,41-43 However, there are currently
no studies that investigate whether the AUC 24h threshold for vancomycin-associated
nephrotoxicity changes when used in the aforementioned special populations. 4 Therefore,
analyses on their vancomycin AUC24h thresholds for nephrotoxicity are warranted.
Critically Ill or ICU Patients
Critically ill patients require larger doses of vancomycin due to their high acuity and their
offending pathogens being less susceptible.13 They also tend to have hemodynamic instability
and renal hypoperfusion that can increase their risk of nephrotoxicity. Furthermore,
vancomycin’s altered volume of distribution (Vd) in critically ill patients increases the risk of
nephrotoxicity.13,38 Critically ill patients with severe sepsis can experience fluid shifts from the
intravascular compartment to the interstitial space due to excessive fluid resuscitation,
widespread endothelial injury, and capillary leakages.13 This results in altering the PK of
hydrophilic drugs like vancomycin by causing an increase in V d and a decrease in plasma
concentration.13,38
Studies demonstrated that variables independently associated with vancomycinassociated nephrotoxicity are ICU residence (aOR, 3.25; 95% CI, 1.18-9.98; p=0.02) and a high
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Acute Physiology and Chronic Health Evaluation (APACHE) II score (22.9 ± 7.4 vs. 18.2 ± 8.5;
p=0.006).16,33 In a retrospective study of 166 patients, Lodise et al. also showed that ICU
patients have a greater than 20% probability of experiencing nephrotoxicity with initial trough
concentrations greater than 10 mg/L.33
Obese Patients
Physiologic changes in obese patients have been shown to alter the V d of vancomycin.39
Obese patients have a higher Vd of vancomycin due to having higher levels of lean body mass
and larger organs than patients of normal weight. 40,44 Despite vancomycin being hydrophilic,
high levels of adipose tissue are also suspected to play a role in increasing the V d. Due to water
accounting for approximately 30% of the content of adipose tissues, vancomycin is able to
distribute in the adipose tissue to a certain extent. 39,40 Additionally, obese patients experience
increased blood flow due to having a higher blood volume and cardiac output. 40 In combination
with vancomycin’s hydrophilic nature, their increased blood flow can contribute to a higher V d.
Currently, there are conflicting studies on the relationship between obesity and the risk of
vancomycin-associated nephrotoxicity. 14,15,42,43,45 In a retrospective study of 207 obese patients
with a body mass index (BMI) greater than 30 kg/m 2 and 323 lean patients, obesity was not
associated with an increased risk of nephrotoxicity (RR, 0.98; 95% CI, 0.93-1.04; p=0.59).45
Contrastingly, there are multiple studies that suggest a relationship between obesity and an
increased risk of vancomycin-associated nephrotoxicity. 14,15,42,43 In a multicenter, retrospective
study of 337 patients, weight greater than 100 kg was found to be an independent predictor of
nephrotoxicity (OR, 2.74; 95% CI, 1.27-5.91).14 In a retrospective study of 270 veterans, Horey
et al. also found weight to be significantly associated with an increased risk of nephrotoxicity
(OR, 1.02; 95% CI, 1.00-1.03).15 Furthermore, Choi et al. demonstrated that obesity class III
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(BMI ≥40 kg/m2) patients have a 3-fold greater risk of vancomycin-associated nephrotoxicity
compared to obesity class I and II (BMI 30-39.9 kg/m 2) patients and nonobese patients (OR,
3.14; 95% CI, 1.27-7.75 and OR, 2.99; 95% CI, 1.12-7.94, respectively). 42 These findings are
consistent with results from a retrospective cohort study of 246 patients conducted by Lodise et
al. which showed that patients who weigh greater than or equal to 101.4 kg were approximately
3.5 times more likely to develop nephrotoxicity (HR, 3.65; 95% CI 2.52-5.28, p<0.001).43 A
mechanistic explanation for obesity being associated with an increased risk of vancomycinassociated nephrotoxicity remains unclear. However, studies hypothesize that a likely factor is
the large Vd that causes disproportionately larger doses of vancomycin and a more intensive
vancomycin exposure profile.42,43
Patients with Preexisting Renal Disease
Patients with preexisting renal disease are at a higher risk of developing vancomycinassociated nephrotoxicity.20 Vancomycin is primarily eliminated renally and its extrarenal
clearance is approximately 5%.17 Vancomycin is predominantly cleared through glomerular
filtration and through active tubular secretion to a certain degree. With a decrease in renal
function, the half-life of vancomycin increases linearly. Thus, patients with preexisting renal
disease have a higher risk of vancomycin accumulating. Normally, the half-life of vancomycin
is six hours. However, in patients with anuria, the half-life can soar up to 100 to 200 hours. As
vancomycin accumulates, there is a higher risk of vancomycin overdosing and subsequent
nephrotoxicity.
Patients on Concomitant Nephrotoxins
Vancomycin has been shown to decrease the threshold for nephrotoxicity and has
demonstrated synergistic activity with other nephrotoxins administered concomitantly. 18,20
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Studies demonstrated that the coadministration of nephrotoxins such as loop diuretics, renin‐
angiotensin system blockers, NSAIDs, aminoglycosides, piperacillin-tazobactam, and IV
contrast dyes increases the risk of renal toxicity. 18,46-50 In a prospective cohort study of 95
patients, Hidayat et al. determined that patients on concomitant nephrotoxins were significantly
associated with an increased risk of nephrotoxicity (91% vs. 20%; p<0.001).19 Even after
performing a multivariate analysis and controlling other significant factors such as age,
APACHE II score, admission to ICU, vancomycin trough concentrations, and duration of
vancomycin therapy, coadministration of nephrotoxins remained the most significant predictor of
nephrotoxicity occurrence (p=0.003).
Matson et al. demonstrated that the concomitant use of loop diuretics, ACEIs, and
NSAIDs increases the risk of vancomycin-associated nephrotoxicity by 43-fold, 5-fold, and 19fold, respectively.18 For aminoglycosides, Rybak et al. assessed 224 patients who received
vancomycin alone, gentamicin alone, or vancomycin plus an aminoglycoside. 47 Patients who
received both vancomycin and an aminoglycoside had a significantly higher rate of
nephrotoxicity than patients who received vancomycin or gentamicin alone (22% vs. 5% vs.
11%, respectively; p<0.05). Similarly, Hanrahan et al. assessed 158 critically ill patients and
demonstrated that concomitant aminoglycosides with vancomycin increased the occurrence of
nephrotoxicity (OR, 18.9; p=0.002).48
Although piperacillin-tazobactam is not considered a nephrotoxin, piperacillintazobactam has been associated with impaired renal recovery and acute interstitial nephritis. 24
Meta-analyses have also suggested that vancomycin with piperacillin-tazobactam can increase
the risk of nephrotoxicity.49,50 Hammond et al. conducted a meta-analysis and analyzed 14
studies.49 They concluded an adjusted OR of 3.11 (95% CI, 1.77-5.47; p<0.001) for
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nephrotoxicity was significant when vancomycin plus piperacillin-tazobactam was compared to
vancomycin plus a beta-lactam antibiotic. Similarly, Giuliano et al. evaluated 15 studies and
calculated an overall OR of 3.65 (95% CI, 2.16-6.17; p<0.001) which was significant when
vancomycin in combination with piperacillin-tazobactam was compared to vancomycin alone. 50

33
CHAPTER 3: METHODOLOGY

Study Design and Population
The study design is a single-institution retrospective cohort study at San Joaquin General
Hospital (SJGH), a 196-bed county hospital located in Stockton, California. The study was
approved by the University of the Pacific (UOP) Institutional Review Board (IRB) with protocol
number 20-122 and by the SJGH IRB with protocol number 20-303. Medical records were
reviewed at SJGH to identify hospitalized patients treated with IV vancomycin between June
2019 to May 2020. Patient identifiable information was removed upon completing the data
collection. Inclusion criteria were patients who were 18 years or older, required vancomycin for
the treatment of an infection, on vancomycin for 48 hours or longer, and had one or more
vancomycin concentrations collected. Exclusion criteria were pregnancy, vancomycin continued
for an infection diagnosed from a previous admission, any form of renal replacement therapy,
vancomycin for surgical prophylaxis, and vancomycin continuous infusion.
Data Collection
Baseline demographics. The following baseline demographics were collected.


Gender



Age



Weight



Height



Ethnicity



Comorbidities (e.g., preexisting liver disease, atherosclerotic cardiovascular disease
[ASCVD], heart failure, diabetes, hypertension, amphetamine use, and IV drug use)
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Clinical characteristics. The following clinical characteristics were collected.


SCr upon initiating vancomycin



Number of days on vancomycin



Suspected or diagnosed infection that indicated the use of vancomycin (e.g., SSTI,
necrotizing fasciitis, osteomyelitis, pneumonia, bacteremia, endocarditis, septic joint,
empyema)

Isolated bacterial species. Based on microbiological reports, patients were categorized
as having MRSA, non-MRSA isolated bacterial species, or no isolated bacterial species.


MRSA: Isolated pathogen was MRSA.



Non-MRSA Isolated Bacterial Species: Isolated pathogen was not MRSA but was
still covered by vancomycin’s spectrum of activity (e.g., Enterococcus spp. and
MSSA).



No Isolated Bacterial Species: Isolated pathogen that is not covered by vancomycin’s
spectrum of activity (e.g., gram-negative bacteria) or no positive cultures obtained
during the hospital stay.

Special populations. Medical charts were reviewed to place patients into vancomycin
special populations of interest: ICU or critically ill patients and obese patients.


ICU or Critically Ill Patients: Patients who required an admission to the medical ICU
or surgical ICU during their vancomycin course of treatment.



Obese Patients: Patients with a BMI greater than or equal to 30 kg/m 2 upon initiating
vancomycin.

Preexisting renal disease and concomitant nephrotoxins. Medical charts were
reviewed to assess for patients with preexisting renal disease and patients on concomitant
nephrotoxins other than vancomycin.


Patients with Preexisting Renal Disease: Patients who have chronic kidney disease or
patients admitted with AKI that was unrelated to vancomycin.
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Patients on a Concomitant Nephrotoxin: Patients who received one or more doses of a
loop diuretic, ACEI, ARB, NSAID, aminoglycoside, piperacillin-tazobactam, or IV
contrast dye while on vancomycin.

Steady state AUC24h. Using the Bayesian software program, PrecisePK (Version
20.02.00, Healthware Inc., San Diego, CA), the patient’s age, gender, weight, height, SCr
history, vancomycin dosing history, and vancomycin trough concentrations were entered into the
program to calculate the AUC24h. By assessing the concentration versus time graph, an interval
when vancomycin’s steady state was reached and consistent was identified. To decrease
variability, the steady state was determined consistent if each of the dose’s peak concentrations
was ±10% of its respective dosing regimen’s total average peak concentration. The AUC 24h for
the steady state interval was then calculated using the equation below.


AUC

𝑖𝑛

∗

∗

=

(

∗

)

(

)

∗ 24 hours

Endpoints. The primary endpoint is vancomycin-associated nephrotoxicity using the
definition of nephrotoxicity from the 2012 KDIGO Clinical Practice Guideline for AKI.


Vancomycin-Associated Nephrotoxicity: An increase in serum creatinine by 0.3
mg/dL or more within 48 hours while on vancomycin or an increase in serum
creatinine by 1.5 times the baseline which is known or presumed to have occurred
within seven days of discontinuing vancomycin.

The secondary endpoint is the estimated vancomycin AUC 24h thresholds for
nephrotoxicity for critically ill or ICU patients, obese patients, patients with preexisting renal
disease, and patients on concomitant nephrotoxins.
The tertiary endpoint is the predictive performances of the vancomycin AUC 24h
thresholds which include the following parameters: 51,52


Positive Predictive Value (PPV): The probability of patients with a positive screening
test truly having the condition. For this study, the PPV is the probability of patients
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with AUC24h values greater than the threshold for nephrotoxicity actually
experiencing vancomycin-associated nephrotoxicity.


Negative Predictive Value (NPV): The probability of patients with a negative
screening test truly not having the condition. For this study, the NPV is the
probability of patients with AUC24h values less than the threshold for nephrotoxicity
actually not experiencing vancomycin-associated nephrotoxicity.



Sensitivity: The proportion of patients with a condition who are correctly identified
by a screening test as truly having that condition (i.e., identifying true positives). For
this study, the sensitivity is the proportion of nephrotoxic patients who are correctly
identified as experiencing vancomycin-associated nephrotoxicity based on the
AUC24h threshold for nephrotoxicity.



Specificity: The proportion of patients without a condition who are correctly
identified by a screening test as truly not having that condition (i.e., identifying true
negatives). For this study, the specificity is the proportion of non-nephrotoxic
patients who are correctly identified as not experiencing vancomycin-associated
nephrotoxicity based on the AUC24h threshold for nephrotoxicity.



Area Under the Receiver Operating Characteristic (ROC) Curve: A combined
measure of sensitivity and specificity which numerically provides the overall
predictive performance of a screening test or diagnostic test. As the area under the
ROC curve increases towards a maximum value of one, the overall performance of
the test increases. For this study, it is the overall predictive performance of the
AUC24h threshold for nephrotoxicity.

Data Analysis
Baseline demographics and clinical characteristics were reported using descriptive
statistics. Additionally, the relationship between the patients’ baseline demographics and clinical
characteristics and vancomycin-associated nephrotoxicity was analyzed by comparing
nephrotoxic patients to non-nephrotoxic patients. The independent t-test was used to detect
statistical differences for continuous data while the Chi-square test and Fisher’s exact test were
used to detect statistical differences for nominal data.
Each special population that included at least ten nephrotoxic patients was further
analyzed to derive the AUC24h threshold where the incidence of nephrotoxicity was most
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disproportionate. The AUC24h thresholds were estimated using CART analysis. Their predictive
performances were assessed by calculating their PPVs, NPVs, sensitivities, and specificities.
The equations below were used to calculate the parameters and an example of the method is
displayed in Table 2.


PPV =

x 100



NPV =

x 100



Sensitivity =

x 100



Specificity =

x 100

Variables: A, true positive; B, false positive; C, false negative; D, true negative

Table 2
Example of Calculating PPV, NPV, Sensitivity, and Specificity for AUC 24h Thresholds Predicting
Nephrotoxicity
AUC24h Threshold of 616 mg*h/L
Nephrotoxic
Non-Nephrotoxic
18
47
Number of Patients
AUC24h above
threshold

True Positive (A)

% Within Threshold
% Within Nephrotoxicity
Number of Patients

AUC24h less than
threshold

27.7%
PPV

62.1%
Sensitivity

False Positive (B)

72.3%
15.3%

11

260

False Negative (C)

True Negative (D)

% Within Threshold

4.1%

% Within Nephrotoxicity

37.9%

95.9%
NPV

84.7%
Specificity

Abbreviations. PPV, positive predictive value; NPV, negative predictive value; AUC 24h, area
under the concentration-time curve over 24 hours.

Each CART-derived threshold’s predictive performance for predicting nephrotoxicity
was then compared to the predictive performance of the AUC 24h threshold of 600 mg*h/L that is
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currently recommended by the 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring
guideline. A generalized score statistic was used to detect statistical differences between the two
thresholds’ PPVs and NPVs and the McNemar test was used to detect statistical differences
between their sensitivities and specificities. When comparing the predictive performances
between the CART-derived thresholds and the guideline threshold, maximizing the PPV and
sensitivity is desired over maximizing the NPV or specificity. A higher PPV increases the
likelihood of identifying AUC24h values that result in nephrotoxicity. Moreover, a higher
sensitivity increases the accuracy of the threshold in predicting patients who truly have
nephrotoxicity and decreases the probability of having a false negative. In addition to comparing
their predictive values, sensitivities, and specificities, ROC curves were analyzed to compare the
thresholds’ overall predictive performances.
Prior to identifying and assessing the AUC24h threshold for each special population, a
validity test was performed to assess the method proposed by this study. This was achieved by
applying the method to the general population. The method was considered validated if the
CART-derived threshold for the general population was determined to be insignificant when
compared to the guideline threshold that was based on preexisting literature.
Lastly, to evaluate for any confounding factors, patients were divided into two groups:
patients who had an AUC24h less than or equal to the CART-derived threshold and those who had
an AUC24h above the CART-derived threshold. Bivariate comparisons between the two groups’
baseline demographics, clinical characteristics, and types of infection were then conducted. The
independent t-test was used to detect statistical differences for continuous data and the Chisquare test and Fisher’s exact test were used to detect statistical differences for nominal data.
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In this study, p-values of less than or equal to 0.05 were considered statistically
significant. Statistical analyses such as the independent t-test, Chi-Square test, Fisher’s exact
test, and CART analysis were performed using IBM SPSS software (Version 27.0, IBM
Corporation, Armonk, NY). The generalized score statistic and McNemar test were performed
using RStudio software (Version 1.3.1073, RStudio Team, Boston, MA).
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CHAPTER 4: RESULTS

Description of Cohort
A total of 336 patients was included in the study. Baseline demographics of the study
population are presented in Table 3. A majority of the patients were male (84.8%) and
Caucasian (41.4%). Among the study population, mean age was 57.1 years (standard deviation
[SD], 14.9 years), mean weight was 86.9 kilograms (SD, 28.1 kilograms), and mean height was
173.0 centimeters (SD, 11.4 centimeters). Common comorbidities included ASCVD (21.7%),
diabetes (33.9%), hypertension (44.9%), and amphetamine use (20.5%).

Table 3
Baseline Demographics
Characteristic
Gender, no. (%)
Male
Female
Age (years), mean ± SD
Weight (kg), mean ± SD
Height (cm), mean ± SD
Ethnicity/Race, no. (%)
Caucasian
Hispanic
Black or African-American
Asian
Mixed
Other
Comorbidity, no. (%)
Preexisting Liver Disease
Atherosclerotic Cardiovascular Disease (ASCVD)
Heart Failure
Diabetes
Hypertension
Amphetamine Use
Intravenous Drug Use

Value for Patients (n=336)
285 (84.8)
51 (15.2)
57.1 ± 14.8
86.9 ± 28.1
173.0 ± 11.4
139 (41.4)
96 (28.6)
66 (19.6)
17 (5.1)
11 (3.3)
7 (2.1)
62 (18.5)
73 (21.7)
40 (11.9)
114 (33.9)
151 (44.9)
69 (20.5)
35 (10.4)
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Clinical characteristics of the study population are illustrated in Table 4. The mean SCr
upon initiating vancomycin was 1.06 mg/dL (SD, 0.69 mg/dL) and the mean duration of therapy
was 7.2 days (SD, 4.6 days). The most common vancomycin indications were SSTI (34.2%),
pneumonia (32.7%), and bacteremia (24.1%), and approximately a quarter of the population’s
isolated pathogens were MRSA (24.1%).

Table 4
Clinical Characteristics
Characteristic
Value for Patients (n=336)
Vancomycin Indication, no. (%)
SSTI
115 (34.2)
Necrotizing Fasciitis
9 (2.7)
Osteomyelitis
33 (9.8)
Pneumonia
110 (32.7)
Bacteremia
81 (24.1)
Endocarditis
5 (1.5)
Septic Joint
6 (1.8)
Empyema
6 (1.8)
Other
43 (12.8)
Isolated Organism, no. (%)
MRSA
81 (24.1)
Non-MRSA
103 (30.7)
No organism isolated or vancomycin-resistant organism
152 (45.2)
Initial Serum Creatinine (mg/dL), mean ± SD
1.06 ± 0.69
Vancomycin Duration (days), mean ± SD
7.2 ± 4.6
Abbreviations. SSTI, skin and soft tissue infections; MRSA, methicillin-resistant
Staphylococcus aureus.

Comparison of Patient Characteristics Between Non-Nephrotoxic and Nephrotoxic Patients
The bivariate comparison of the baseline demographics and clinical characteristics
between patients who had nephrotoxicity and those who did not is displayed in Table 5.
Twenty-nine (8.6%) patients experienced nephrotoxicity. Patients who experienced
nephrotoxicity were more likely to have preexisting renal disease (34.5% vs. 14.4%; p=0.014)
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and had significantly higher SCr levels upon initiating vancomycin (1.52 ± 0.95 mg/dL vs. 1.02
±. 0.65 mg/dL; p<0.001). Furthermore, the nephrotoxic group had significantly more critically
ill or ICU patients (75.9% vs. 30.6%; p<0.001) and patients who received concomitant loop
diuretics (75.9% vs. 33.9%; p<0.001).
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Table 5
Patient Characteristics Between Non-Nephrotoxic and Nephrotoxic Patients
Non-Nephrotoxic Nephrotoxic
Characteristic
P-value
(n=307)
(n=29)
Demographics
Age (years), mean ± SD
56.7 ± 14.7
60.5 ± 14.7
0.186a
Male, no. (%)
260 (84.7)
25 (86.2)
1.000b
Selected Comorbidities
Preexisting Liver Disease, no. (%)
57 (18.6)
5 (17.2)
0.860
ASCVD, no. (%)
64 (20.8)
9 (31.0)
0.203
Heart Failure, no. (%)
31 (10.1)
9 (31.0)
0.003b*
Diabetes, no. (%)
101 (32.9)
13 (44.8)
0.195
Hypertension, no. (%)
130 (42.3)
21 (72.4)
0.002*
Selected Special Populations
Critically Ill or ICU, no. (%)
94 (30.6)
22 (75.9)
<0.001*
2
Obese (BMI≥30 kg/m ), no. (%)
101 (32.9)
10 (34.5)
0.862
Preexisting Renal Disease, no. (%)
44 (14.4)
10 (34.5)
0.014b*
Concomitant Nephrotoxin
Loop Diuretic, no. (%)
104 (33.9)
22 (75.9)
<0.001*
ACEI/ARB, no. (%)
68 (22.2)
6 (20.7)
0.849
NSAID, no. (%)
41 (13.4)
3 (10.3)
1.000b
Aminoglycoside, no. (%)
7 (2.3)
2 (6.9)
0.177b
Piperacillin/tazobactam, no. (%)
12 (3.9)
0 (0)
0.610b
IV Contrast, no. (%)
135 (44.0)
7 (24.1)
0.039*
Vancomycin Treatment Data
Initial SCr (mg/dL), mean ± SD
1.02 ± 0.65
1.52 ± 0.95
<0.001a*
Vancomycin Indication
SSTI, no. (%)
109 (35.5)
6 (20.7)
0.108
Osteomyelitis, no. (%)
31 (10.1)
2 (6.9)
0.753b
Pneumonia, no. (%)
95 (30.9)
15 (51.7)
0.023*
Bacteremia, no. (%)
77 (25.1)
4 (13.8)
0.174
Vancomycin Duration (days), mean ± SD
7.1 ± 4.6
7.4 ± 4.5
0.775a
*
P-value was <0.05.
a
P-value was calculated using independent t-test.
b
P-value was calculated using Fisher’s exact test due to one or more expected values being <5.
All other p-values were calculated using chi-square test.
Abbreviations. ASCVD, atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI,
angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID,
nonsteroidal anti-inflammatory drug; SSTI, skin and soft tissue infection; SCr, serum creatinine.
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Method Validation by Analyzing the General Population
For the general population of 336 patients, the CART analysis showed that the incidence
of nephrotoxicity was significantly higher for patients with AUC 24h values greater than 616
mg*h/L (27.7% vs. 4.1%; p<0.001) (Figure 1).

Figure 1. CART-derived AUC24h nephrotoxicity threshold for the general population.

Table 6, Table 7, and Figure 2 compare the predictive performances of the CARTderived threshold and guideline threshold. No statistical differences were detected between their
PPVs (p=0.163), NPVs (p=0.286), and sensitivities (p=0.157). Moreover, their overall
predictive performances were noninferior to one another as they had similar areas under the ROC
curves (0.734 vs. 0.747; p=0.589). The threshold of 616 mg*h/L was consistent with previous
studies and was associated with practically similar predictive performances to the guideline
threshold of 600 mg*h/L.4
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Table 6
Predictive Performances of CART-Derived AUC 24h Threshold and Guideline Threshold for the
General Population
Predictive Performance
AUC24h 616 mg*h/L AUC24h 600 mg*h/L P-value
PPV (%)
27.7
25.0
0.163a,c
NPV (%)
95.9
96.5
0.286a,d
Sensitivity (%)
62.1
69.0
0.157b,e
Specificity (%)
84.7
80.5
<0.001b,f*
Area under ROC Curve (95% CI) 0.734 (0.626–0.841)
0.747 (0.646–0.849)
0.589g
*
P-value was <0.05
a
P-value was calculated using generalized score statistic.
b
P-value was calculated using McNemar test.
c
PPV data derived from 145 observations (65 patients with AUC 24h >616 mg*h/L and 80
patients with AUC24h >600 mg*h/L).
d
NPV data derived from 527 observations (271 patients with AUC 24h <616 mg*h/L and 256
patients with AUC24h <600 mg*h/L).
e
Sensitivity data derived from 29 nephrotoxic patients.
f
Specificity data derived from 307 non-nephrotoxic patients.
g
ROC analysis derived from 336 patients.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; PPV, positive
predictive value; NPV, negative predictive value; ROC, receiver operating characteristic.

Figure 2. Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold
and guideline AUC24h threshold for the general population.
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Table 7
AUC24h of General Population That Experienced Nephrotoxicity
AUC24h ≤600 mg*h/L
AUC24h >600 mg*h/L
AUC24h ≤616 mg*h/L
9 (31.0)
2 (6.9)
AUC24h >616 mg*h/L
0 (0)
18 (62.1)
P-value=0.157 (based on McNemar test); n=29
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours.

Special Populations and Nephrotoxic Patients
Table 8 summarizes the total number of patients and patients with nephrotoxicity in each
special population. Special populations of interest included critically ill or ICU patients (34.5%),
obese patients (33.0%), patients with preexisting renal disease (16.1%), and patients on
concomitant nephrotoxins (76.8%). The most common concomitant nephrotoxins were loop
diuretics (37.5%), ACEIs or ARBs (22.0%), and IV contrast dyes (42.3%).
There were at least ten nephrotoxic patients in critically ill or ICU patients, obese
patients, patients with preexisting renal disease, and patients on concomitant loop diuretics. The
CART-derived AUC24h thresholds were derived for these special populations and their predictive
performances were assessed, as described in the method section. Contrastingly, less than ten
nephrotoxic patients were observed in patients on concomitant ACEIs or ARBs, NSAIDs,
aminoglycosides, piperacillin-tazobactam, or IV contrast dyes. Due to inadequate sample sizes
in these special populations, further analyses were not performed.
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Table 8
Special Populations and Nephrotoxic Patients
Special Population

Total Patients, no.

Nephrotoxic Patients, no.

Critically Ill or ICU Patient
116
22
Obese Patient (BMI≥30 kg/m2)
111
10
Patient with Preexisting Renal Disease
54
10
Patient on a Concomitant Nephrotoxin
Loop Diuretic
126
22
ACEI/ARB
74
6
NSAID
44
3
Aminoglycoside
9
2
Piperacillin/tazobactam
12
0
IV Contrast Dye
142
7
Abbreviations. ICU, intensive care unit; BMI, body mass index; NSAID, nonsteroidal antiinflammatory drug; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II
receptor blocker; IV, intravenous.

CART-Derived Vancomycin AUC24h Thresholds for Nephrotoxicity
Critically Ill or ICU Patients
Of the 336 patients, 116 (34.5%) patients were identified to be critically ill or ICU
patients. The CART analysis showed that incidence of nephrotoxicity was significantly higher
for critically ill or ICU patients with AUC24h values greater than 544 mg*h/L (35.8% vs. 4.8%;
p<0.001) (Figure 3).
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Figure 3. CART-derived AUC24h nephrotoxicity threshold for critically ill and ICU patients.

Table 9 and Figure 4 display the predictive performances of the CART-derived AUC 24h
threshold and guideline threshold for critically ill or ICU patients. The CART-derived threshold
had a significantly higher NPV (p=0.037) and sensitivity (p=0.031). In other words, out of 22
ICU patients with nephrotoxicity, the threshold of 544 mg*h/L identified six (27.3%) more
nephrotoxic patients than the threshold of 600 mg*h/L (Table 10). Moreover, the overall
predictive performance of the CART-derived threshold was shown to be 0.058 (8.4%) higher
than that of the guideline threshold based on the ROC curve analysis (0.751 vs. 0.693; p=0.278).
Statistical significance for the ROC analysis was not achieved due to a small sample size.
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Table 9
Predictive Performances of CART-Derived AUC 24h Threshold and Guideline Threshold for
Critically Ill and ICU Patients
Predictive Performance
AUC24h 544 mg*h/L AUC24h 600 mg*h/L P-value
PPV (%)
35.8
40.6
0.337a,c
NPV (%)
95.2
89.3
0.037a,d*
Sensitivity (%)
86.4
59.1
0.014b,e*
Specificity (%)
63.8
79.8
<0.001b,f*
Area under ROC Curve (95% CI) 0.751 (0.646–0.856)
0.694 (0.563–0.825)
0.278g
*
P-value was <0.05
a
P-value was calculated using generalized score statistic.
b
P-value was calculated using McNemar test.
c
PPV data derived from 85 observations (53 patients with AUC 24h >544 mg*h/L and 32 patients
with AUC24h >600 mg*h/L).
d
NPV data derived from 147 observations (63 patients with AUC 24h <544 mg*h/L and 84
patients with AUC24h <600 mg*h/L).
e
Sensitivity data derived from 22 nephrotoxic patients.
f
Specificity data derived from 94 non-nephrotoxic patients.
g
ROC analysis derived from 116 patients.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; ICU, intensive
care unit; PPV, positive predictive value; NPV, negative predictive value; ROC, receiver
operating characteristic.

Figure 4. Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold
and guideline AUC24h threshold for critically ill and ICU patients.
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Table 10
AUC24h of Critically Ill or ICU Patients Who Experienced Nephrotoxicity
AUC24h ≤600 mg*h/L
AUC24h >600 mg*h/L
AUC24h ≤544 mg*h/L
3 (13.6)
0 (0)
AUC24h >544 mg*h/L
6 (27.3)
13 (59.1)
P-value=0.014 (based on McNemar test); n=22
Abbreviations. ICU, intensive care unit; AUC24h, area under the concentration-time curve over
24 hours.

Table 11 provides the bivariate comparison between critically ill or ICU patients with
AUC24h values less than or equal to 544 mg*h/L and those with AUC 24h values greater than 544
mg*h/L. No confounding factors were found that can impact the risk of vancomycin-associated
nephrotoxicity between the two groups.
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Table 11
Patient Characteristics Between Critically Ill or ICU Patients with AUC 24h Above and Below
CART-Derived AUC24h Threshold
AUC24h ≤544
AUC24h >544
Characteristic
mg*h/L
mg*h/L
P-value
(n=63)
(n=53)
Demographics
Age (years), mean ± SD
53.7 ± 16.0
60.1 ± 14.7
0.028a*
Male, no. (%)
53 (84.1)
41 (77.4)
0.354
Selected Comorbidities
Preexisting Liver Disease, no. (%)
6 (9.5)
8 (15.1)
0.359
ASCVD, no. (%)
15 (23.8)
10 (18.9)
0.519
Heart Failure, no. (%)
5 (7.9)
12 (22.6)
0.026*
Diabetes, no. (%)
19 (30.2)
8 (15.1)
0.056
Hypertension, no. (%)
23 (36.5)
23 (43.4)
0.450
Selected Special Populations
Obese (BMI≥30 kg/m2), no. (%)
23 (36.5)
15 (28.3)
0.348
Preexisting Renal Disease, no. (%)
9 (14.3)
14 (26.4)
0.103
Concomitant Nephrotoxin, no. (%)
Loop Diuretic, no. (%)
34 (54.0)
37 (69.8)
0.081
ACEI/ARB, no. (%)
10 (15.9)
6 (11.3)
0.479
NSAID, no. (%)
4 (6.3)
7 (13.2)
0.209
Aminoglycoside, no. (%)
4 (6.3)
3 (5.7)
1.000b
Piperacillin/tazobactam, no. (%)
4 (6.3)
1 (1.9)
0.374
IV Contrast, no. (%)
26 (41.3)
21 (39.6)
0.857
Vancomycin Treatment Data
Initial SCr (mg/dL), mean ± SD
1.12 ± 1.05
1.20 ± 0.78
0.649a
Vancomycin Indication
SSTI, no. (%)
9 (14.3)
7 (13.2)
0.867
Osteomyelitis, no. (%)
2 (3.2)
3 (5.7)
0.659b
Pneumonia, no. (%)
31 (49.2)
30 (56.6)
0.427
Bacteremia, no. (%)
17 (27.0)
11 (20.8)
0.435
Vancomycin Duration (days), mean ± SD
8.2 ± 4.3
9.0 ± 6.1
0.397a
Nephrotoxicity, no. (%)
3 (4.8)
19 (35.8)
<0.001*
*
P-value was <0.05
a
P-value was calculated using independent t-test.
b
P-value was calculated using Fisher’s exact test due to one or more expected values being <5.
All other p-values were calculated using chi-square test.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; ASCVD,
atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, angiotensin-convertingenzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, nonsteroidal anti-inflammatory
drug; SSTI, skin and soft tissue infection; SCr, serum creatinine.
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Obese Patients
Of the 336 patients, 111 (33.0%) patients were identified to be obese and had a mean
BMI of 38.2 kg/m2 (SD, 9.2 kg/m2). The CART analysis showed that incidence of
nephrotoxicity was significantly higher for obese patients with AUC 24h values greater than 586
mg*h/L (25.8% vs. 2.5%; p<0.001) (Figure 5).

Figure 5. CART-derived AUC24h nephrotoxicity threshold for obese patients.

Table 12, Table 13, and Figure 6 show no statistical difference between the predictive
performances of the CART-derived threshold and guideline threshold. No statistical differences
were found between their PPVs (p=0.968), NPVs (p=0.357), sensitivities (p=0.317), and
specificities (p=0.083). Additionally, the two thresholds had a difference in areas under the
ROC curves of 0.035 (4.7%) and their overall predictive performances were noninferior to one
another (0.786 vs. 0.751; p=0.488).
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Table 12
Predictive Performances of CART-Derived AUC 24h Threshold and Guideline Threshold for
Obese Patients
Predictive Performance
AUC24h 586 mg*h/L AUC24h 600 mg*h/L P-value
PPV (%)
25.8
25.9
0.968a,c
NPV (%)
97.5
96.4
0.357a,d
Sensitivity (%)
80.0
70.0
0.317b,e
Specificity (%)
77.2
80.2
0.083b,f
Area under ROC Curve (95% CI) 0.786 (0.635–0.938) 0.751 (0.579–0.923)
0.278g
a
P-value was calculated using generalized score statistic.
b
P-value was calculated using McNemar test.
c
PPV data derived from 58 observations (31 patients with AUC 24h >586 mg*h/L and 27 patients
with AUC24h >600 mg*h/L).
d
NPV data derived from 164 observations (80 patients with AUC 24h <586 mg*h/L and 84
patients with AUC24h <600 mg*h/L).
e
Sensitivity data derived from 10 nephrotoxic patients.
f
Specificity data derived from 101 non-nephrotoxic patients.
g
ROC analysis derived from 111 patients.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; PPV, positive
predictive value; NPV, negative predictive value; ROC, receiver operating characteristic.

Figure 6. Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold
and guideline AUC24h threshold for obese patients.
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Table 13
AUC24h of Obese Patients Who Experienced Nephrotoxicity
AUC24h ≤600 mg*h/L
AUC24h >600 mg*h/L
AUC24h ≤586 mg*h/L
2 (20.0)
0 (0)
AUC24h >586 mg*h/L
1 (10.0)
7 (70.0)
P-value=0.317 (based on McNemar test); n=10
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours.

The bivariate comparison of obese patients with AUC 24h values less than or equal to 586
mg*h/L versus those with AUC24h values greater than 586 mg*h/L is displayed in Table 14. No
confounding factors that can impact the risk of vancomycin-associated nephrotoxicity between
the two groups were found.
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Table 14
Patient Characteristics Between Obese Patients with AUC 24h Above and Below CART-Derived
AUC24h Threshold
AUC24h ≤586.4 AUC24h >586.4
Characteristic
mg*h/L
mg*h/L
P-value
(n=80)
(n=31)
Demographics
Age (years), mean ± SD
54.1 ± 15.0
57.8 ± 9.0
0.201a
Male, no. (%)
67 (83.8)
26 (83.9)
0.988
2
BMI (kg/m ), mean ± SD
37.7 ± 8.6
43.2 ± 14.0
0.071a
Selected Comorbidities
Preexisting Liver Disease, no. (%)
12 (15.0)
7 (22.6)
0.341
ASCVD, no. (%)
12 (15.0 )
4 (12.9)
1.000b
Heart Failure, no. (%)
8 (10.0)
7 (22.6)
0.119b
Diabetes, no. (%)
33 (41.3)
15 (48.4)
0.496
Hypertension, no. (%)
37 (46.3)
17 (54.8)
0.526
Selected Special Populations
Critically Ill or ICU, no. (%)
28 (35.0)
10 (32.3)
0.785
Preexisting Renal Disease, no. (%)
12 (15.0)
11 (35.5)
0.017a
Concomitant Nephrotoxin, no. (%)
Loop Diuretic, no. (%)
41 (51.2)
15 (48.4)
0.787
ACEI/ARB, no. (%)
21 (26.3)
6 (19.4)
0.447
NSAID, no. (%)
18 (22.5)
7 (22.6)
0.993
Aminoglycoside, no. (%)
4 (5.0)
1 (3.2)
1.000b
Piperacillin/tazobactam, no. (%)
2 (2.5)
1 (3.2)
1.000b
IV Contrast, no. (%)
40 (50.0)
14 (45.2)
0.647
Vancomycin Treatment Data
Initial SCr (mg/dL), mean ± SD
1.13 ± 0.97
1.46 ± 0.83
0.102a
Vancomycin Indication
SSTI, no. (%)
35 (43.8)
11 (35.5)
0.428
Osteomyelitis, no. (%)
10 (12.5)
3 (9.7)
1.000b
Pneumonia, no. (%)
23 (28.7)
7 (22.6)
0.511
Bacteremia, no. (%)
18 (22.5)
10 (32.3)
0.288
Vancomycin Duration (days), mean ± SD
6.8 ± 3.4
8.3 ± 7.7
0.141a
Nephrotoxicity, no. (%)
2 (2.5)
8 (25.8)
<0.001*
*
P-value was <0.05
a
P-value was calculated using independent t-test.
b
P-value was calculated using Fisher’s exact test due to one or more expected values being <5.
All other p-values were calculated using chi-square test.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; BMI, body mass
index; ASCVD, atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI,
angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID,
nonsteroidal anti-inflammatory drug; SSTI, skin and soft tissue infection; SCr, serum creatinine.
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Patients with Preexisting Renal Disease
Of the 336 patients, 54 (16.1%) patients were considered to have preexisting chronic
kidney disease or AKI upon admission. The CART analysis showed that incidence of
nephrotoxicity was significantly higher for patients with AUC 24h values greater than 539
mg*h/L (31.2% vs. 0%; p=0.003) (Figure 7).

Figure 7. CART-derived AUC24h nephrotoxicity threshold for patients with preexisting renal
disease.

Table 15 and Figure 8 compare the predictive performance of the CART-derived
AUC24h threshold and guideline threshold for patients with preexisting renal disease. The
CART-derived threshold had a significantly higher NPV (p=0.025) and sensitivity (p=0.025). In
other words, out of ten nephrotoxic patients with preexisting renal disease, the threshold of 539
mg*h/L identified five (50.0%) more nephrotoxic patients than the guideline threshold of 600
mg*h/L (Table 16). Although statistical significance was not achieved due to a small sample
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size, the overall predictive performance of the 539 mg*h/L threshold was shown to be 0.148
(24.6%) higher than that of the 600 mg*h/L threshold (0.750 vs. 0.602; p=0.096).

Table 15
Predictive Performances of CART-Derived AUC 24h Threshold and Guideline Threshold for
Patients with Preexisting Renal Disease
Predictive Performance
AUC24h 539 mg*h/L AUC24h 600 mg*h/L P-value
PPV (%)
31.3
27.8
0.653a,c
NPV (%)
100
86.1
0.025a,d*
Sensitivity (%)
100
50.0
0.025b,e*
Specificity (%)
50.0
70.5
0.003b,f*
Area under ROC Curve (95% CI) 0.750 (0.617–0.883) 0.602 (0.401–0.803)
0.096g
*
P-value was <0.05
a
P-value was calculated using generalized score statistic.
b
P-value was calculated using McNemar test.
c
PPV data derived from 50 observations (32 patients with AUC 24h >539 mg*h/L and 18 patients
with AUC24h >600 mg*h/L).
d
NPV data derived from 58 observations (22 patients with AUC 24h <539 mg*h/L and 36 patients
with AUC24h <600 mg*h/L).
e
Sensitivity data derived from 10 nephrotoxic patients.
f
Specificity data derived from 44 non-nephrotoxic patients.
g
ROC analysis derived from 54 patients.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; PPV, positive
predictive value; NPV, negative predictive value; ROC, receiver operating characteristic.

Figure 8. Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold
and guideline AUC24h threshold for patients with preexisting renal disease.
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Table 16
AUC24h of Patients with Preexisting Renal Disease Who Experienced Nephrotoxicity
AUC24h ≤600 mg*h/L
AUC24h >600 mg*h/L
AUC24h ≤539 mg*h/L
0 (0)
0 (0)
AUC24h >539 mg*h/L
5 (50.0)
5 (50.0)
P-value=0.025 (based on McNemar test); n=10
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; ICU, intensive
care unit.

Table 17 shows no confounding factors that can impact the risk of vancomycinassociated nephrotoxicity between the patients with AUC24h values less than or equal to the
CART-derived threshold and those with AUC24h values above the CART-derived threshold.
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Table 17
Patient Characteristics Between Patients with Preexisting Renal Disease with AUC 24h Above and
Below CART-Derived AUC24h Threshold
AUC24h ≤539
AUC24h >539
Characteristic
mg*h/L
mg*h/L
P-value
(n=22)
(n=32)
Demographics
Age (years), mean ± SD
60.7 ± 12.3
65.0 ± 13.8
0.240a
Male, no. (%)
21 (95.5)
27 (84.4)
0.383b
Selected Comorbidities
Preexisting Liver Disease, no. (%)
3 (13.6)
9 (28.1)
0.320b
ASCVD, no. (%)
9 (40.9)
8 (47.1)
0.216
Heart Failure, no. (%)
4 (18.2)
11 (34.4)
0.192
Diabetes, no. (%)
10 (45.5)
12 (37.5)
0.559
Hypertension, no. (%)
14 (63.6)
24 (75.0)
0.369
Selected Special Populations
Critically Ill or ICU
9 (40.9)
14 (43.8)
0.836
Obese (BMI≥30 kg/m2), no. (%)
7 (31.8)
15 (50.0)
0.184
Concomitant Nephrotoxin
Loop Diuretic, no. (%)
14 (63.6)
16 (50.0)
0.322
ACEI/ARB, no. (%)
5 (22.7)
6 (18.8)
0.743b
NSAID, no. (%)
2 (9.5)
4 (12.5)
1.000b
Aminoglycoside, no. (%)
0 (0)
1 (3.1)
1.000b
Piperacillin/tazobactam, no. (%)
0 (0)
2 (6.3)
0.508
IV Contrast, no. (%)
4 (18.2)
4 (12.5)
0.702b
Vancomycin Treatment Data
Initial SCr (mg/dL), mean ± SD
2.13 ± 1.53
1.94 ± 0.90
0.559a
Vancomycin Indication
SSTI, no. (%)
6 (27.3)
14 (43.8)
0.218
Osteomyelitis, no. (%)
1 (4.5)
3 (9.4)
0.638b
Pneumonia, no. (%)
12 (54.5)
12 (37.5)
0.215
Bacteremia, no. (%)
3 (13.6)
5 (15.6)
1.000b
Vancomycin Duration (days), mean ± SD
7.0 ± 3.1
6.53 ± 3.5
0.613a
Nephrotoxicity, no. (%)
0 (0)
10 (31.3)
0.003b*
*
P-value was <0.05
a
P-value was calculated using independent t-test.
b
P-value was calculated using Fisher’s exact test due to one or more expected values being <5.
All other p-values were calculated using chi-square test.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; ASCVD,
atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, angiotensin-convertingenzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, nonsteroidal anti-inflammatory
drug; SSTI, skin and soft tissue infection; SCr, serum creatinine.
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Patients on Concomitant Loop Diuretics
The CART-derived AUC24h threshold for nephrotoxicity for the 126 (37.5%) patients on
a concomitant loop diuretic was 543 mg*h/L. Incidence of nephrotoxicity was significantly
higher for patients with AUC24h values greater than 543 mg*h/L (34.5% vs. 2.9%; p<0.001)
(Figure 9).

Figure 9. CART-derived AUC24h nephrotoxicity threshold for patients on concomitant loop
diuretics.

Table 18 and Figure 10 provide the predictive performances of the CART-derived
threshold and guideline threshold for patients on a concomitant loop diuretic. The CARTderived threshold had a significantly higher NPV (p=0.028) and sensitivity (p=0.014). In other
words, out of 22 nephrotoxic patients on a concomitant loop diuretic, the threshold of 543
mg*h/L identified six (27.3%) more nephrotoxic patients than the guideline threshold (Table
19). Although statistical significance was not met due to the small sample size, the ROC curve
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analysis showed that the CART-derived threshold’s overall predictive performance was 0.055
(7.7%) higher than that of the guideline threshold (0.772 vs. 0.717; p=0.292).

Table 18
Predictive Performances of CART-Derived AUC 24h Threshold and Guideline Threshold for
Patients on Concomitant Loop Diuretics
Predictive Performance
AUC24h 543 mg*h/L AUC24h 600 mg*h/L P-value
PPV (%)
34.5
40.0
0.235a,c
NPV (%)
97.1
91.2
0.028a,d*
Sensitivity (%)
90.9
63.6
0.014b,e*
Specificity (%)
63.5
79.8
<0.001b,f*
Area under ROC Curve (95% CI) 0.772 (0.677-0.867)
0.717 (0.591-0.844)
0.292g
*
P-value was <0.05
a
P-value was calculated using generalized score statistic.
b
P-value was calculated using McNemar test.
c
PPV data derived from 93 observations (58 patients with AUC 24h >543 mg*h/L and 35 patients
with AUC24h >600 mg*h/L).
d
NPV data derived from 159 observations (68 patients with AUC 24h <543 mg*h/L and 91
patients with AUC24h <600 mg*h/L).
e
Sensitivity data derived from 22 nephrotoxic patients.
f
Specificity data derived from 104 non-nephrotoxic patients.
g
ROC analysis derived from 126 patients.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; PPV, positive
predictive value; NPV, negative predictive value; ROC, receiver operating characteristic.

Figure 10. Receiver operating characteristic (ROC) curves of CART-derived AUC24h threshold
and guideline AUC24h threshold for patients on concomitant loop diuretics.
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Table 19
AUC24h of Patients on Concomitant Loop Diuretics Who Experienced Nephrotoxicity
AUC24h ≤600 mg*h/L
AUC24h >600 mg*h/L
AUC24h ≤543 mg*h/L
2 (9.1)
0 (0)
AUC24h >543 mg*h/L
6 (27.3)
14 (63.6)
P-value=0.014 (based on McNemar test); n=22
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours.

No confounding factors were found when comparing patients on concomitant loop
diuretics with AUC24h values less than or equal to 543 mg*h/L to those with AUC 24h values
greater than 543 mg*h/L (Table 20).
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Table 20
Patient Characteristics Between Patients on Concomitant Loop Diuretics with AUC 24h Above
and Below CART-Derived AUC24h Threshold
AUC24h ≤543 AUC24h >543
Characteristic
mg*h/L
mg*h/L
P-value
(n=68)
(n=58)
Demographics
Age (years), mean ± SD
58.9 ± 13.8
62.2 ± 14.8
0.189a
Male, no. (%)
63 (92.6)
14 (77.6)
0.016*
Selected Comorbidities
Preexisting Renal Disease, no. (%)
14 (20.6)
16 (27.6)
0.358
Preexisting Liver Disease, no. (%)
15 (22.1)
9 (15.5)
0.351
ASCVD, no. (%)
17 (25.0)
14 (24.1)
0.911
Heart Failure, no. (%)
12 (17.6)
21 (36.2)
0.018*
Diabetes, no. (%)
25 (36.8)
14 (24.1)
0.126
Hypertension, no. (%)
37 (54.4)
34 (58.6)
0.635
Selected Special Populations
Critically Ill or ICU, no. (%)
34 (50.0)
37 (63.8)
0.120
Obese (BMI≥30), no. (%)
34 (50.0)
22 (37.9)
0.174
Amputee, no. (%)
7 (10.3)
5 (8.6)
0.750
Vancomycin Treatment Data
Initial SCr (mg/dL), mean ± SD
1.22 ± 1.03
1.29 ± 0.80
0.664a
Vancomycin Indication
SSTI, no. (%)
16 (23.5)
16 (27.6)
0.602
Osteomyelitis, no. (%)
3 (4.4)
4 (6.9)
0.702b
Pneumonia, no. (%)
35 (51.5)
30 (51.7)
0.977
Bacteremia, no. (%)
16 (23.5)
10 (17.2)
0.385
Vancomycin Duration (days), mean ± SD
8.2 ± 4.0
9.1 ± 7.4
0.426a
Nephrotoxicity, no. (%)
2 (2.9)
20 (34.5)
<0.001*
*
P-value <0.05
a
P-value was calculated using independent t-test.
b
P-value was calculated using Fisher’s exact test due to one or more expected values being <5.
All other p-values were calculated using chi-square test.
Abbreviations. AUC24h, area under the concentration-time curve over 24 hours; ASCVD,
atherosclerotic cardiovascular disease; ICU, intensive care unit; ACEI, angiotensin-convertingenzyme inhibitor; ARB, angiotensin II receptor blocker; NSAID, nonsteroidal anti-inflammatory
drug; SSTI, skin and soft tissue infection; SCr, serum creatinine.
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CHAPTER 5: DISCUSSION

This retrospective cohort study identified and examined the vancomycin AUC 24h
thresholds for nephrotoxicity for critically ill patients, obese patients, patients with preexisting
renal disease, and patients on concomitant nephrotoxins. It is the first study to perform analyses
on vancomycin special populations to assess for AUC 24h thresholds for nephrotoxicity that differ
from the guideline threshold of 600 mg*h/L. Compared to previous studies of a similar nature,
this study adopted a less stringent definition of vancomycin-associated nephrotoxicity to capture
more nephrotoxic patients.8,12,32-36 Previous studies defined vancomycin-associated
nephrotoxicity as an increase in SCr by 0.5 mg/dL or more or a 50% increase from baseline on
two or more consecutive measures. On the other hand, this study adapted the definition of AKI
from the 2012 KDIGO Clinical Practice Guideline for AKI and defined vancomycin-associated
nephrotoxicity as an increase in SCr by 0.3 mg/dL or more within 48 hours or a 50% increase
from baseline which is known or presumed to have occurred within seven days of discontinuing
vancomycin.37 Among the 336 patients included, 29 (8.6%) patients met the definition of
nephrotoxicity. Consistent with prior studies’ findings, an increased risk of nephrotoxicity was
associated with critical illness, preexisting renal disease, higher initial serum creatinine levels,
and concomitant loop diuretics.
Previous studies used various AUC parameters (e.g., AUC 0-24h, AUC24-48h, and AUC24h)
and methods to assess their CART-derived AUC thresholds. 8,12,32-36 Prior to analyzing the
special populations, the general population was analyzed to validate the method proposed in this
study. For the general population, a CART-derived AUC 24h threshold of greater than 616
mg*h/L was significantly associated with an increased risk of nephrotoxicity. The difference in
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predictive performances between the CART-derived threshold and guideline threshold was not
statistically significant. No statistical differences were detected between the two thresholds’
PPVs, NPVs, sensitivities, and areas under the ROC curves. Because the threshold of 616
mg*h/L was consistent with preexisting literature, the proposed method to estimate the CARTderived AUC24h thresholds for nephrotoxicity and to assess their predictive performances was
validated.
Although PPV, NPV, sensitivity, and specificity were estimated, PPV and sensitivity
were given greater weight when determining the threshold for nephrotoxicity with the optimal
predictive performance. For predicting nephrotoxicity, a higher PPV increases the likelihood of
identifying patients with vancomycin exposures that result in nephrotoxicity. In addition, a
higher sensitivity increases the accuracy of the AUC24h threshold in detecting a true positive for
nephrotoxicity and decreases the probability of having a false negative.
Critically ill patients frequently need larger doses of vancomycin due to their high acuity
and their typically more resistant pathogens.13,41 Additionally, they are more inclined to have
hemodynamic instability, renal hypoperfusion, and an increased V d of vancomycin that can
increase their risk of nephrotoxicity. ICU residence and high APACHE II scores are
independently associated with an increased risk of nephrotoxicity (aOR, 3.25; 95% CI, 1.189.98; p=0.02 and 22.9 ± 7.4 vs. 18.2 ± 8.5; p=0.006, respectively).16,33 In this study, a CARTderived threshold of 544 mg*h/L was identified for critically ill patients. Compared to the
guideline threshold, the CART-derived threshold had a similar PPV and a significantly higher
sensitivity. Therefore, this study demonstrates that a lower vancomycin AUC 24h threshold than
the guideline threshold of 600 mg*h/L should be considered in critically ill patients to decrease
the risk of nephrotoxicity.
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Currently, there are conflicting studies on the relationship between obesity and the risk of
nephrotoxicity. Davies et al. did not associate obesity with an increased risk of nephrotoxicity
(RR, 0.98; 95% CI, 0.93-1.04; p=0.59).45 The current study also did not associate obesity with
an increased risk of nephrotoxicity (32.9% vs. 34.5%, p=0.862). However, other studies have
shown weight to be associated with an increased risk of nephrotoxicity (OR, 1.02; 95% CI, 1.001.03) and weight greater than 100 kg was an independent predictor of nephrotoxicity (OR, 2.74;
95% CI, 1.27-5.91).14,15 Researchers hypothesize that the increased risk of nephrotoxicity is due
to obese patients having an increased Vd of vancomycin that leads to disproportionately larger
doses and a more intensive vancomycin exposure profile.42,43 However, the AUC24h parameter
already accounts for vancomycin dosing and is directly proportional to the amount of
vancomycin administered. Thus, even if obesity is associated with an increased risk of
nephrotoxicity, the AUC24h threshold for nephrotoxicity is suspected to not be lowered in obese
patients. In this study, a significant CART-derived threshold was not identified for obese
patients. Compared to the guideline threshold, the CART-derived threshold of 586 mg*h/L did
not have a statistically significant PPV, NPV, sensitivity, specificity, or area under the ROC
curve. Therefore, this study supports the continued use of 600 mg*h/L as the AUC 24h threshold
for nephrotoxicity in obese patients.
Studies have shown that patients with preexisting renal disease are associated with a
higher risk of nephrotoxicity as vancomycin is predominantly eliminated renally. 17,20 A
significant CART-derived threshold of 539 mg*h/L was identified in patients with preexisting
renal disease. Compared to the guideline threshold, the AUC 24h threshold of 539 mg*h/L had a
comparable PPV and a significantly higher sensitivity. To minimize the risk of vancomycin-
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associated nephrotoxicity, this study supports using a lower vancomycin AUC 24h threshold than
the guideline threshold of 600 mg*h/L in patients with preexisting renal disease.
A prospective study determined that patients on concomitant nephrotoxins were
significantly associated with an increased risk of nephrotoxicity (91% vs. 20%; p<0.001).19
Concomitant nephrotoxins remained a significant predictor of nephrotoxicity after performing a
multivariate analysis (p=0.003). Concomitant loop diuretics increase the risk of vancomycinassociated nephrotoxicity by 43-fold.18 The current study identified a significant CART-derived
threshold of 543 mg*h/L for patients on concomitant loop diuretics. The CART-derived
threshold had a comparable PPV but a significantly higher sensitivity compared to the guideline
threshold. For patients on concomitant loop diuretics, a lower vancomycin AUC 24h threshold
than the guideline threshold of 600 mg*h/L should be considered to minimize the risk of
nephrotoxicity.
Other concomitant nephrotoxins such as renin-angiotensin system blockers, NSAIDs,
aminoglycosides, piperacillin-tazobactam, and IV contrast dyes have also demonstrated
synergistic activity with vancomycin in the development of nephrotoxicity. 18,20,48-50 However,
less than ten nephrotoxic patients were observed and therefore CART analysis was not
performed in these special populations. With the exception of patients on IV contrast dyes, these
special populations had less than ten nephrotoxic patients due to their small sample sizes.
Despite having an adequate sample size of patients who received IV contrast dyes, less than 10
nephrotoxic patients were observed. This was hypothesized to be due to patients commonly
receiving sodium bicarbonate or acetylcysteine prior to receiving IV contrast dyes at SJGH to
minimize the risk of nephrotoxicity. Further research is needed to determine if the upper AUC 24h
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threshold is consistent or varies when used in patients on concomitant ACEIs, ARBs, NSAIDs,
aminoglycosides, piperacillin-tazobactam, or IV contrast dyes.
The CART-derived thresholds identified for critically ill patients, patients with
preexisting renal disease, and patients on concomitant loop diuretics are inherently able to
provide AUC24h thresholds where the risk of nephrotoxicity is most disproportionate. However,
studies theorize that the incidence of vancomycin-associated nephrotoxicity increases along the
AUC24h continuum.4 Therefore, it is important to recognize that the study’s findings of AUC 24h
thresholds that are lower than the guideline threshold serve as a guidance for clinicians to be
cognizant of the potential synergistic nephrotoxicity risk when dosing vancomycin in special
populations such as critically ill patients, patients with preexisting renal disease, and patients on
concomitant loop diuretics. Clinicians should consider dosing vancomycin more conservatively
in these special populations.
Study Limitations
The current study has several limitations that are mostly inherent to the study’s singlecenter, retrospective study design. Foremost, a majority of the patients were male and
Caucasian. However, no study has reported significantly different AUC 24h thresholds for
nephrotoxicity based on gender or race. Based on statistical analysis using this study’s
population, the incidence of nephrotoxicity was not significantly different between males and
females (p=0.828) and between Caucasians and non-Caucasians (p=0.145). Therefore, the
dominant male and Caucasian population may not limit the application of the current study to
females or other races.
Moreover, not all of the patients included in the nephrotoxicity analysis had
Staphylococcus aureus infections. Patients on vancomycin due to suspected MRSA but then
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finalized with other gram-positive or gram-negative pathogens were still included in the
nephrotoxicity analysis. However, the inclusion of non-MRSA infections was considered
appropriate as the main endpoint measurement was nephrotoxicity rather than efficacy of the
drug exposure. In addition, it mimics real-life clinical practice settings where causative
pathogens are commonly yet to be identified during the initial course of vancomycin.
Additionally, trough concentrations were primarily used to estimate the Bayesian-derived
AUC24h rather than both peak and trough concentrations. However, Ho et al. demonstrated
significant correlations between the Bayesian-derived AUC 24h values estimated from one sample
and those from two samples (p <0.001).53 Therefore, the CART-derived AUC24h thresholds
derived from predominately trough concentrations would not be meaningfully different from
those derived from peak and trough concentrations.
Lastly, this study did not include the AUC24h/MICBMD threshold for efficacy of
vancomycin. This outcome had been planned in the early state of the research and the study
initially aimed to identify the CART-derived AUC24h/MICBMD thresholds associated with
treatment success in MRSA-associated infections and special populations such as critically ill
patients, amphetamine users, IVDU, and patients on concomitant immunosuppressants.
However, only 13 (3.9%) patients had clinical failure. Furthermore, only 81 (24.3%) patients
were isolated with MRSA and 17 (21.0%) of those patients had AUC 24h/MICBMD ratios less than
400. Therefore, this study focused only on the AUC 24h threshold for nephrotoxicity.
Future Directions
As more hospitals continue to transition from trough-based monitoring to AUC 24h-based
monitoring, further studies should be conducted to establish a relationship between the
vancomycin AUC24h threshold for nephrotoxicity and special populations such as critically ill
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patients, obese patients, patients with preexisting renal disease, and patients on concomitant
nephrotoxins. Additional studies should also be conducted to assess the impact on the AUC 24h
threshold when patients meet the description of more than one special population.
A follow-up multicenter, prospective study is warranted to validate the lower CARTderived AUC24h that was identified in critically ill patients, patients with preexisting renal
disease, and patients on concomitant loop diuretics. The impact on the AUC 24h threshold when
patients meet the description of more than one special population should also be considered.
Furthermore, conducting the study at multiple institutions can increase the sample size of the
study. Having more nephrotoxic patients in each special population can improve the estimation
of the CART-derived thresholds for nephrotoxicity and the assessment of their predictive
performances. Additionally, it will allow further analyses on special populations that the current
study was unable to analyze (e.g., patients on concomitant ACEIs, ARBs, NSAIDs,
aminoglycosides, piperacillin-tazobactam, or IV contrast dyes). Moreover, collecting both peak
and trough concentrations would be ideal to maximize the accuracy of estimating the AUC 24h.
Additional parameters can also be collected to better describe the special populations. For
example, a scoring system such as the APACHE II can be used to stratify critically ill patients
based on the severity of their critical illness. Similarly, recording the dose and duration of the
concomitant nephrotoxins can help determine if conservative vancomycin dosing needs to be
considered in patients who receive a single dose or low doses of a concomitant nephrotoxin.
A multicenter, prospective study is also needed to investigate the generalizability of the
proposed vancomycin AUC24h/MICBMD threshold of 400 for clinical efficacy in different MRSAassociated infections and vancomycin special populations. This will ensure that the study is
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adequately powered and includes enough incidences of MRSA infections and clinical failures to
estimate the CART-derived thresholds for clinical efficacy.
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CHAPTER 6: CONCLUSION

For critically ill patients, patients with preexisting renal disease, and patients on
concomitant loop diuretics, a lower vancomycin AUC24h threshold for nephrotoxicity such as
544 mg*h/L, 539 mg*h/L, and 543 mg*h/L, respectively, may be considered to minimize the
risk of nephrotoxicity. Compared to the vancomycin AUC 24h threshold of 600 mg*h/L that is
currently recommended by the 2020 ASHP/IDSA/PIDS/SIDP updated vancomycin monitoring
guideline, these thresholds had comparable PPVs but significantly higher sensitivities. On the
other hand, this study supports the continued use of the vancomycin AUC 24h threshold of 600
mg*h/L to minimize the risk of nephrotoxicity in obese patients.

73
REFERENCES

1. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult
patients: A consensus review of the american society of health-system pharmacists, the
infectious diseases society of america, and the society of infectious diseases pharmacists.
American journal of health-system pharmacy: AJHP: official journal of the American
Society of Health-System Pharmacists Website. 2009.
2. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in
patients with methicillin-resistant staphylococcus aureus bacteremia: Support for consensus
guidelines suggested targets. Clin Infect Dis. 2011; 52(8):975-981. doi: 10.1093/cid/cir124.
3. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery
of vancomycin in individual patients. Adv Drug Deliv Rev. 2014; 77:50-57. doi:
10.1016/j.addr.2014.05.016.
4. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin: A revised
consensus guideline and review of the american society of health-system pharmacists, the
infectious diseases society of america, the pediatric infectious diseases society and the
society of infectious diseases pharmacists. Website. 2019.
5. Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus
area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents
Chemother. 2018; 62(2). doi: 10.1128/AAC.02042-17.
6. Finch NA, Zasowski EJ, Murray KP, et al. A quasi-experiment to study the impact of
vancomycin area under the concentration-time curve-guided dosing on vancomycinassociated nephrotoxicity. Antimicrobial agents and chemotherapy. 2017; 61(12). doi:
10.1128/AAC.01293-17.
7. Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus
area under the curve to determine therapeutic vancomycin dosing. Antimicrobial agents and
chemotherapy. 2018; 62(2). doi: 10.1128/AAC.02042-17.
8. Suzuki Y, Kawasaki K, Sato Y, et al. Is peak concentration needed in therapeutic drug
monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with
methicillin-resistant staphylococcus aureus pneumonia. Chemotherapy. 2012; 58(4):308-312.
doi: 10.1159/000343162.
9. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial
vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin
Infect Dis. 2009; 49(4):507-514. doi: 10.1086/600884.
10. Aljefri DM, Avedissian SN, Rhodes NJ, Postelnick MJ, Nguyen K, Scheetz MH.
Vancomycin area under the curve and acute kidney injury: A meta-analysis. Clin Infect Dis.
2019; 69(11):1881-1887. doi: 10.1093/cid/ciz051.
11. Neely MN, Youn G, Jones B, et al. Are vancomycin trough concentrations adequate for
optimal dosing? Antimicrob Agents Chemother. 2014; 58(1):309-316. doi:
10.1128/AAC.01653-13.
12. Mogle BT, Steele JM, Seabury RW, Dang UJ, Kufel WD. Implementation of a two-point
pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients
with methicillin-resistant staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2018;
52(6):805-810. doi: 10.1016/j.ijantimicag.2018.08.024.

74
13. Álvarez O, Plaza-Plaza JC, Ramirez M, Peralta A, Amador CA, Amador R. Pharmacokinetic
assessment of vancomycin loading dose in critically ill patients. Antimicrob Agents
Chemother. 2017; 61(8). doi: 10.1128/AAC.00280-17.
14. Hall RG, Hazlewood KA, Brouse SD, et al. Empiric guideline-recommended weight-based
vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant
staphylococcus aureus bacteremia: A retrospective cohort study. BMC Pharmacol Toxicol.
2013; 14:12. doi: 10.1186/2050-6511-14-12.
15. Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to
vancomycin trough serum concentrations in a veteran's population: A retrospective analysis.
Ann Pharmacother. 2012; 46(11):1477-1483. doi: 10.1345/aph.1R158.
16. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of
possible renal toxicity associated with vancomycin in patients with health care-associated
methicillin-resistant staphylococcus aureus pneumonia. Clin Ther. 2007; 29(6):1107-1115.
doi: 10.1016/j.clinthera.2007.06.014.
17. Luque Y, Mesnard L. [Vancomycin nephrotoxicity: Frequency and mechanistic aspects].
Nephrol Ther. 2018; 14 Suppl 1:S133-S138. doi: 10.1016/j.nephro.2018.02.009.
18. Matson KL, Shaffer CL, Beck GL, Simonsen KA. Assessment of initial serum vancomycin
trough concentrations and their association with initial empirical weight-based vancomycin
dosing and development of nephrotoxicity in children: A multicenter retrospective study.
Pharmacotherapy. 2015; 35(3):337-343. doi: 10.1002/phar.1552.
19. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin
therapy for methicillin-resistant staphylococcus aureus infections: Efficacy and toxicity. Arch
Intern Med. 2006; 166(19):2138-2144. doi: 10.1001/archinte.166.19.2138.
20. Gupta A, Biyani M, Khaira A. Vancomycin nephrotoxicity: Myths and facts. Neth J Med.
2011; 69(9):379-383.
21. Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with
methicillin-resistant staphylococcus aureus bloodstream infections: How much is enough?
Clin Infect Dis. 2014; 59(5):666-675. doi: 10.1093/cid/ciu398.
22. Schumacher GE, Barr JT. Bayesian approaches in pharmacokinetic decision making. Clin
Pharm. 1984; 3(5):525-530.
23. Turner RB, Kojiro K, Shephard EA, et al. Review and validation of bayesian doseoptimizing software and equations for calculation of the vancomycin area under the curve in
critically ill patients. Pharmacotherapy. 2018; 38(12):1174-1183. doi: 10.1002/phar.2191.
24. Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol
Ther. 2017; 102(3):459-469. doi: 10.1002/cpt.726.
25. Singh NB, Yim J, Jahanbakhsh S, Sakoulas G, Rybak MJ. Impact of cefazolin coadministration with vancomycin to reduce development of vancomycin-intermediate
staphylococcus aureus. Diagn Microbiol Infect Dis. 2018; 91(4):363-370. doi:
10.1016/j.diagmicrobio.2018.03.020.
26. Jung Y, Song K, Cho Je, et al. Area under the concentration-time curve to minimum
inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillinresistant staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2014; 43(2):179-183.
doi: 10.1016/j.ijantimicag.2013.10.017.
27. Holmes NE, Turnidge JD, Munckhof WJ, et al. Vancomycin AUC/MIC ratio and 30-day
mortality in patients with staphylococcus aureus bacteremia. Antimicrob Agents Chemother.
2013; 57(4):1654-1663. doi: 10.1128/AAC.01485-12.

75
28. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of
vancomycin and other antimicrobials in patients with staphylococcus aureus lower
respiratory tract infections. Clin Pharmacokinet. 2004; 43(13):925-942. doi:
10.2165/00003088-200443130-00005.
29. Casapao AM, Lodise TP, Davis SL, et al. Association between vancomycin day 1 exposure
profile and outcomes among patients with methicillin-resistant staphylococcus aureus
infective endocarditis. Antimicrob Agents Chemother. 2015; 59(6):2978-2985. doi:
10.1128/AAC.03970-14.
30. Brown J, Brown K, Forrest A. Vancomycin AUC24/MIC ratio in patients with complicated
bacteremia and infective endocarditis due to methicillin-resistant staphylococcus aureus and
its association with attributable mortality during hospitalization. Antimicrob Agents
Chemother. 2012; 56(2):634-638. doi: 10.1128/AAC.05609-11.
31. Gawronski KM, Goff DA, Brown J, Khadem TM, Bauer KA. A stewardship program's
retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance
in patients with methicillin-resistant staphylococcus aureus bacteremia and osteomyelitis.
Clin Ther. 2013; 35(6):772-779. doi: 10.1016/j.clinthera.2013.05.008.
32. Allen D, Townsend M, Drew R. Relationship between vancomycin area under the
concentration-time curve (AUC) and nephrotoxicity in adults. Open Forum Infectious
Diseases. 2017; 4(suppl_1):S295-S295. doi: 10.1093/ofid/ofx163.676.
33. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial
vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Clinical Infectious Diseases. 2009; 49(4):507-514. doi: 10.1086/600884.
34. Zasowski EJ, Murray KP, Trinh TD, et al. Identification of vancomycin exposure-toxicity
thresholds in hospitalized patients receiving intravenous vancomycin. Antimicrob Agents
Chemother. 2018; 62(1). doi: 10.1128/AAC.01684-17.
35. Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ. Establishment of an AUC0–24
threshold for nephrotoxicity is a step towards individualized vancomycin dosing for
methicillin-resistant staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2017;
61(5). doi: 10.1128/AAC.02535-16.
36. Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The emperor's new clothes: Prospective
observational evaluation of the association between initial vancomycin exposure and failure
rates among adult hospitalized patients with MRSA bloodstream infections (PROVIDE).
Clin Infect Dis. 2019. doi: 10.1093/cid/ciz460.
37. KDIGO clinical practice guideline for acute kidney injury. Official Journal of the
International Society of Nephrology. 2012; 2(1):1-138.
38. Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria
for early acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2008;
23(4):1203-1210. doi: 10.1093/ndt/gfm744.
39. Durand C, Bylo M, Howard B, Belliveau P. Vancomycin dosing in obese patients: Special
considerations and novel dosing strategies. Ann Pharmacother. 2018; 52(6):580-590. doi:
10.1177/1060028017750084.
40. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: What
we have learned over the past 30 years. J Antimicrob Chemother. 2012; 67(6):1305-1310.
doi: 10.1093/jac/dks066.
41. Bamgbola O. Review of vancomycin-induced renal toxicity: An update. Ther Adv
Endocrinol Metab. 2016; 7(3):136-147. doi: 10.1177/2042018816638223.

76
42. Choi YC, Saw S, Soliman D, et al. Intravenous vancomycin associated with the development
of nephrotoxicity in patients with class III obesity. Ann Pharmacother. 2017; 51(11):937944. doi: 10.1177/1060028017720946.
43. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four
grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob
Agents Chemother. 2008; 52(4):1330-1336. doi: 10.1128/AAC.01602-07.
44. Masich AM, Kalaria SN, Gonzales JP, et al. Vancomycin pharmacokinetics in obese patients
with sepsis or septic shock. Pharmacotherapy. 2020; 40(3):211-220. doi: 10.1002/phar.2367.
45. Davies SW, Efird JT, Guidry CA, et al. Vancomycin-associated nephrotoxicity: The obesity
factor. Surg Infect (Larchmt). 2015; 16(6):684-693. doi: 10.1089/sur.2014.198.
46. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin
therapy for methicillin-resistant staphylococcus aureus infections: Efficacy and toxicity. Arch
Intern Med. 2006; 166(19):2138-2144. doi: 10.1001/archinte.166.19.2138.
47. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone
and with an aminoglycoside. J Antimicrob Chemother. 1990; 25(4):679-687. doi:
10.1093/jac/25.4.679.
48. Hanrahan TP, Kotapati C, Roberts MJ, et al. Factors associated with vancomycin
nephrotoxicity in the critically ill. Anaesth Intensive Care. 2015; 43(5):594-599. doi:
10.1177/0310057X1504300507.
49. Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, Bookstaver PB. Systematic review
and meta-analysis of acute kidney injury associated with concomitant vancomycin and
piperacillin/tazobactam. Clin Infect Dis. 2017; 64(5):666-674. doi: 10.1093/cid/ciw811.
50. Giuliano CA, Patel CR, Kale-Pradhan PB. Is the combination of piperacillin-tazobactam and
vancomycin associated with development of acute kidney injury? A meta-analysis.
Pharmacotherapy. 2016; 36(12):1217-1228. doi: 10.1002/phar.1851.
51. Park SH, Goo JM, Jo C. Receiver operating characteristic (ROC) curve: Practical review for
radiologists. Korean J Radiol. 2004; 5(1):11-18. doi: 10.3348/kjr.2004.5.1.11.
52. Trevethan R. Sensitivity, specificity, and predictive values: Foundations, pliabilities, and
pitfalls in research and practice. Frontiers in public health. 2017; 5:307. doi:
10.3389/fpubh.2017.00307.
53. Ho D, Arquiette J, Kim M. Bayesian-estimated vancomycin area under the curve using a
single trough concentration versus 2 concentrations. American Journal of Health-System
Pharmacy. In press.

